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Formation of free radicals is ubiquitous and amongst the various free radicals, 
reactive nitrogen species (RNS) derived radicals are highly reactive and have been 
linked to endogenous human carcinogenesis. Induction of apoptosis has also been 
observed in cultures of macrophages and pancreatic P-cells exposed to RNS. 
Macrophages exposed to nitric oxide, one of the derivative of RNS, exhibited typical 
morphology and showed DNA fragmentation exhibiting apoptotic cell death, 
indicating that nitric oxide plays an important role in the onset of mutagenesis and 
involvement of these processes in cancer and other inflammatory diseases, like e.g. 
SLE. It has also been reported that NO production is increased in patients with active 
SLE, which is characterized by immune activated state. Patients with SLE showed up-
regulation of iNOS in normal appearing vascular endothelium. These endothelium 
also over-express the vascular adhesion molecules ICAM-1, selectin and VCAM. 
Biosynthesis of nitric oxide takes place by the conversion of L-arginine to L-
citrulline thereby releasing a small molecule with an unpaired electron and a short 
half life. This conversion or production of NO is catalyzed by the enzyme nitric oxide 
synthase which exists in three isoforms: neuronal, endothelial, and inducible. 
In this study aqueous solution of human DNA in PBS at physiological pH was 
exposed to RNS generated by synergistic action of SNP and pyrogallol. The RNS 
generated in the cciurse of reaction was peroxynitrite, since polyhydroxy aromatic 
compounds auto-oxidize to produce semiquinones which react with dioxygen to 
generate 02" . Simultaneous generation of 02'" and NO leads to the production of 
peroxynitrite (0N00~) which is a potent oxidant with t '/z < 1 sec and is capable of 
reacting with almost all cellular biomolecules. 
The structural and conformational alterations in DNA following exposure to 
RNS were studied by UV and fluorescence spectroscopy, simple and alkaline agarose 
gel electrophoresis, nuclease SI sensitivity, quenching and thermal denaturation 
studies. 
The UV spectra of RNS-DNA exhibited hyperchromicity at X^ax suggesting 
free radical induced base modification. Thermal denaturation studies showed that 
DNA, as a result of modification, has lost some of its stability as exemplified by 
decrease in Tm and early onset of duplex melting. Structural alterations in DNA 
following damage by various agents may at times render the molecule susceptible to 
single strand specific nuclease. Simple and alkaline agarose gel electrophoresis 
clearly showed that upon modification the DNA helix looses some of its stability due 
to generation of single strand breaks which render it susceptible to alkali and nuclease 
SI digestion . The combined action of the two species i.e. SNP and pyrogallol leading 
to the generation of peroxynitrite radical was confirmed by quenching studies. 
Unlike native DNA, RNS-DNA was found to be highly immunogenic, 
inducing high titre (>1:12800) antibodies in rabbits. Thus it can be inferred that 
human DNA is transformed into an immunogenic state following exposure to RNS. 
Anti RNS-DNA antibodies, though highly specific for the immunogen, 
mimicked SLE autoantibodies by showing considerable cross reactivity towaids 
native DNA, synthetic polynucleotides as well as nuclear proteins. This polyspecific 
behaviour of induced antibodies could be due to some common aniigenic 
determinants on the immunogen and the cross reacting antigen. 
Antigenicity of RNS-DNA was further investigated by characterizing SLE 
autoantibodies, botli through competition ELISA and gel retardation assay which 
revealed greater specificity of circulating SLE autoantibodies towards RNS-DNA. 
Since it has been established that DNA damage which goes unrepaired may 
lead to carcinogenesis, antibodies fi^om different types of cancer were checked for 
their binding to the native and modified DNA. Recognition of circulating antibodies 
obtained from the sera of patients suffering from different types of cancer, by 
modified DNA was appreciably higher as compared to the unmodified form which 
clearly shows that cancer patients harbour antibodies which are recognizing the 
altered/modified/damaged DNA structure arising as a result of modification. The 
specificity of the antibody binding was further proved via competitive binding studies. 
Sera of vaiious cancer patients with carcinoma of different origin were 
screened for the presence of circulating antibodies against native and modified DNA. 
It was observed, through direct binding and competition ELISA studies, that in almost 
all the cases binding was more pronounced with modified DNA. 
The recognition of native and RNS-DNA by cancer and SLE autoantibodies 
was visually detected in band shift assay. Increased formation of high molecular 
weight immune complexes by cancer and SLE IgG with RNS-DNA as compared to 
the native DNA clearly indicate higher recognition of modified DNA by human 
autoantibodies prevalent in patients suffering fi-om cancer and SLE. 
The role ol' RNS in development of cancer was further investigated by 
isolating DNA from blood of cancer patients and studying its binding with the 
induced antibodies (anti-RNS-DNA IgG). DNA isolated from the cancer patients 
exhibited enhanced recognition of the induced antibodies as compared to the DNA 
obtained from normal healthy individuals. 
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Formation of free radicals is ubiquitous and amongst the various free radicals, 
reactive nitrogen species (RNS) derived radicals are highly reactive and have been 
linked to endogenous human carcinogenesis. Induction of apoptosis has also been 
observed in cultures of macrophages and pancreatic P-cells exposed to RNS. 
Macrophages exposed to nitric oxide, one of the derivative of RNS, exhibited typical 
morphology and showed DNA fragmentation exhibiting apoptotic cell death, 
indicating that nitric oxide plays an important role in the onset of mutagenesis and 
involvement of these processes in cancer and other inflammatory diseases, like e.g. 
SLE. It has also b&sn reported that NO production is increased in patients with active 
SLE, which is characterized by immune activated state. Patients with SLE showed up-
regulation of iNOS in normal appearing vascular endothelium. These endothelium 
also over-express the vascular adhesion molecules ICAM-1, selectin and VCAM. 
Biosynthesis of nitric oxide takes place by the conversion of L-arginine to L-
citrulline thereby releasing a small molecule with an unpaired electron and a short 
half life. This conversion or production of NO is catalyzed by the enzyme nitric oxide 
synthase which exists in three isoforms: neuronal, endothelial, and inducible. 
In this studj' aqueous solution of human DNA in PBS at physiological pH was 
exposed to RNS generated by synergistic action of SNP and pyrogallol. The RNS 
generated in the course of reaction was peroxynitrite, since polyhydroxy aromatic 
compounds auto-oxidize to produce semiquinones which react with dioxygen to 
generate 02". Simultaneous generation of O2'" and NO leads to the production of 
peroxynitrite (ONOO") which is a potent oxidant with t '/i < 1 sec and is capable of 
reacting with almost all cellular biomolecules. 
The structural and conformational alterations in DNA following exposure to 
RNS were studied by UV and fluorescence spectroscopy, simple and alkaline agarose 
gel electrophoresis, nuclease SI sensitivity, quenching and thermal denaturation 
studies. 
The UV spectra of RNS-DNA exhibited hyperchromicity at Xmax suggesting 
free radical induced base modification. Thermal denaturation studies showed that 
DNA, as a result of modification, has lost some of its stability as exemplified by 
decrease in Tm and early onset of duplex melting. Structural alterations in DNA 
following damage by various agents may at times render the molecule susceptible to 
single strand specific nuclease. Simple and alkaline agarose gel electrophoresis 
clearly showed that upon modification the DNA helix looses some of its stability due 
to generation of single strand breaks which render it susceptible to alkali and nuclease 
SI digestion . The combined action of the two species i.e. SNP and pyrogallol leading 
to the generation of peroxynitrite radical was confirmed by quenching studies. 
Unlike native DNA, RNS-DNA was found to be highly immunogenic, 
inducing high tit re (>1:12800) antibodies in rabbits. Thus it can be inferred that 
human DNA is transformed into an immunogenic state following exposure to RNS. 
Anti RNSl-DNA antibodies, though highly specific for the immunogen, 
mimicked SLE autoantibodies by showing considerable cross reactivity towards 
native DNA, synthetic polynucleotides as well as nuclear proteins. This polyspecific 
behaviour of induced antibodies could be due to some common antigenic 
determinants on the immunogen and the cross reacting antigen. 
Antigenicity of RNS-DNA was further investigated by characterizing SLE 
autoantibodies, both through competition ELISA and gel retardation assay which 
revealed greater specificity of circulating SLE autoantibodies towards RNS-DNA. 
Since it has been established that DNA damage which goes unrepaired may 
lead to carcinogenesis, antibodies fi"om different types of cancer were checked for 
their binding to the native and modified DNA. Recognition of circulating antibodies 
obtained fi"om the sera of patients suffering from different types of cancer, by 
modified DNA was appreciably higher as compared to the unmodified form which 
clearly shows that cancer patients harbour antibodies which are recognizing the 
altered/modified/damaged DNA structure arising as a result of modification. The 
specificity of the antibody binding was further proved via competitive binding studies. 
Sera of various cancer patients with carcinoma of different origin were 
screened for the ]3resence of circulating antibodies against native and modified DNA. 
It was observed, through direct binding and competition ELISA studies, that in almost 
all the cases binding was more pronounced with modified DNA. 
The recogjaition of native and RNS-DNA by cancer and SLE autoantibodies 
was visually det(5Cted in band shift assay. Increased formation of high molecular 
weight immune complexes by cancer and SLE IgG with RNS-DNA as compared to 
the native DNA clearly indicate higher recognition of modified DNA by human 
autoantibodies prevalent in patients suffering from cancer and SLE. 
The role of RNS in development of cancer was further investigated by 
isolating DNA from blood of cancer patients and studying its binding with the 
induced antibodies (anti-RNS-DNA IgG). DNA isolated from the cancer patients 
exhibited enhanced recognition of the induced antibodies as compared to the DNA 
obtained from normal healthy individuals. 
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All the systems maintain and transfer their genetic information through a thread 
like macromolecular structure known as deoxyribonucleic acid or DNA. The basic 
structure of DNA was elucidated by Watson and Crick in 1953 which has had the way to 
understanding gene function in molecular terms. The Watson and Crick B-helix is the 
most accepted model in solution. The structure of nucleic acids, in solution, cannot be 
directly predicted from their crystal or fiber structures since it depends on the variation of 
environmental condition such as solvent, pH, temperature and ionic strength. (Fukudome 
et al., 1990; Zhong and Johnson, 1990). Since DNA is made up of ordinary molecules 
that are not endowoJ with any peculiar kind of quantum mechanical stability, it can 
attain different conformations such as A-and C-DNA, within the right handed family 
(Adams 1996) or Z-DNA, which is a left handed double helix, so called because the 
phosphates in the backbone are zig-zagged and have alternating purine and pyrimidine. It 
has been demonstrated that deoxyguanosine moieties play an important role in producing 
left handed Z-structures in poly (dG-dC) (Wang et al, 1979) while the deoxyguanosine 
residues are responsible for the poly (dA).poly(dT) conformational transitions 
(Nakamura et al., 1985). A triple helical form called H-DNA has also been reported 
(Frank-Kamentski, 1990). The various conformations of DNA are in equilibrium with 
each other (Dickerson et al., 1982; Rich et al., 1984; Pechenaya, 1993). The change in 
conformation of DNA from B -> Z is one of the examples of DNA polymorphism 
(Pietrasanta et al., 1994). Among the different conformations of DNA, B and Z type do 
occur in vivo but majority is in the B-form (Jaworski et al., 1987; Drew et al., 1988). A-
DNA is usually fonried when relative humidity is below 75% i.e. dehydration favours 
B->A transition (Table 1). Also the conformation of poly(dG). poly(dG) in solution is A-
like (Sarma et al., 1986), the dormant spores of Bacillus harbour A-DNA (Setlow, 
1992). As said earlier, DNA is highly flexible macromolecule and therefore capable of 
interacting with oth(;r macromolecules and attaining different conformations. DNA 
undergoing transcription forms DNA-RNA hybrids and double helical RNA hair pins, 
which have mostly A-DNA type structure (Travers, 1989.) 
Immunogenicitj/ of DNA 
Immunogenicity is not an intrinsic property of an antigen but rather depends on a 
number of properties of the particular biological system that an antigen encounters. 
TABLE 1 
Different Conformations of Right Handed DNA 
FORM 
A (Na - salt ,75% relative humidity) 
B (Na - salt ,92% relative humidity) 
C ( Li - salt, 66% relative humidity) 
RNA-DNA hybrid 
PITCH 
(A°) 
28 
34 
31 
28 
RESIDUE 
PER TURN 
11 
10 
9.3 
11 
INCLINATION OF 
BASE PAIR FROM 
HORIZONTAL 
20° 
0° 
6° 
20° 
Source : Adams et al. (1981) 
Immunogenicity is mainly determined by four properties of a molecule namely (i) its 
foreignness (ii) molecular size (iii) chemical complexity and (iv) ability to be processed 
and presented with an MHC molecule on the surface of an antigen presenting cell or 
altered self cell. The antigenic properties of nucleic acid were recognized after finding 
circulating immune complexes in the sera of patients with systemic lupus erythematosus 
(SLE) in which native DNA was found to bind with SLE autoantibodies. The anti-DNA 
antibodies found in SLE sera are known to be polyspecific and have been shown to 
recognize epitopes; that occur not only on differing nucleic acids (Andrezewski et al., 
1991) but also on phospholipids (Tiikainem et al., 1991), proteins (Tsuzaka et al., 1996), 
polysaccharides (Jlashihara et al., 1993) and cell membrane structures (Jacob et al., 
1986). This polyspecificity / polyreactivity of anti DNA autoantibodies could be due to 
variable binding sites in individual immunoglobulin or to recurrent epitopes in different 
antigens. The polyreactivity of anti-DNA autoantibodies suggest that DNA itself may not 
be the immunogen responsible for anti-DNA antibodies. To study this enigma several 
experiments were conducted to account for the immunogenicity of DNA. Attempts to 
induce antibody foimation by injection of free nucleic acid or nucleic acid with Freunds 
adjuvant but without any carrier have led to variable results. Immunization of rabbits 
with calf thymus DNA did not elicit antibody response (Haskowa et al., 1959, Wilson et 
al., 1965). Also, they got negative results on injection of purified native or denatured 
salmon, calf thymus, phage T4 or E.coli DNA. Later it was found that immunization with 
a mixture of denatured DNA and methylated bovine serum albumin (MBSA), with or 
without adjuvant, kiad to the formation of antibodies that reacted with denatured DNA 
but not with native DNA (Plescia et al., 1964). This enhancement of immunogenicity of 
nucleic acid could be due to the fact that MBSA acts as a carrier that allows its delivery 
to appropriate cell for antibody formation and also it may protect DNA fi-om degradation 
by nucleases. Immunization of rabbits with right handed poly(dG-dC).poly(dG-dC) 
triggered the immune response leading to the production of antibodies that were specific 
for the polymer but failed to react with either denatured DNA or calf thymus DNA 
(Lafer and Stollar, 1984 ; Zarling et al., 1984). Thus it could be said that complexes of 
double helical polynucleotides with MBSA were effective immunogens that differ from 
DNA in some aspects of B-conformation. Besides these, DNA complexes with a 
synthetic immunogenic peptide, Fus-1, induces an anti-double stranded DNA response in 
mice (Desai et al., 1993). This led to the conclusion that antigen drive in lupus involves 
either a substance other than native DNA or DNA in a form (e.g. nucleosome), that is not 
readily mimicked by artificial complexes (Burlingame et al, 1993; Mohan et al, 1993). 
Besides these, DNA modified with hormones, drugs and ROS have also been reported to 
induce antibodies (Moinuddin and Ali, 1994; Arjumand et al., 1995; Ashok and Ali, 
1998). Certain nucleic acid polymers like poly(dT), poly(dC), poly(dA), poly(dl) and 
poly(dG) can induce antibodies that react selectively with the immunogen (Garg and Ali, 
1998). It has been Deported that naturally occurring human anti-DNA autoantibodies bind 
to P-estradial and native DNA suggesting that female sex hormone plays a role in the 
etiopathogenesis of SLE (Moinuddin et al., 1998). Besides this, there is compelling 
evidence that bacterial DNA, in contrast to mammalian DNA, can induce variety of 
responses in both normal humans and animals (Pisetsky, 1996). Contrary to prevailing 
Dogma that anti-DNA antibodies occur only in SLE, the normal human sera showed 
significant binding to DNA from two bacterial species. Micrococcus lysodectikus and 
staphylococcus epidermidis. Bacterial DNA in contrast to mammalian DNA induces 
variety of responses in humans as well as in animals. This may be due to the differences 
between two DNA, bacterial DNA contain sequences that are rarely found in mammalian 
DNA. Prokaryotic DNA contains a high frequency of methylated adenosine residue 
which are much less abundant in mammalian DNA (Pisetsky et al., 1989). These 
methylated bases promote unique conformations. Mammalian DNA in contrast contains 
methylated C in CpG doublets to much greater extent than bacterial DNA. This is 
especially relevant because poly (CG) with methylated C is much less mitogenic than 
poly (CG) with urunethylated C. It is well known that CG rich DNA has tendency to 
form Z-DNA which is highly immunogenic. However, methylation of C residues hinders 
the formation of Z-conformation (Messina et al., 1993). Therefore unmethylated CpG 
sequences are especially mitogenic and immunogenic. Reduced methylation of the C's in 
CpG either due to failure to methylate C's in certain genes or due to demethylation of 
CpG's as a result of gene activation results in generation of immunogenic DNA in SLE. 
Studies have shown £ind inferred that normal human sera display high titers of antibodies 
that bind to antigenic determinants on certain bacterial DNA. The antibodies in these 
sera are highly specific for the different bacterial DNA antigen (Karounos et al., 1988), 
in contrast to SLE sera which recognize determinants widely present on both 
mammalian and bacterial DNA. An interesting observation is that antibodies to bacterial 
DNA in normal human sera are predominantly IgG2 type whereas lupus anti-DNA 
antibodies are mainly IgGl and IgG3 type (Gilkeson et al., 1991). These different IgG 
subclasses are encoded by different genes hence it can be said that the two DNA acting 
as antigens activate different germ line CH genes. Among these subtypes IgGl and IgG3 
readily cross placenta and are effective complement activators, they bind with high 
affinity to FC receptor on phagocytic cells and thus mediate opsonization. Whereas, 
IgG2 cannot cross placenta and is less effective complement activator. Therefore, it can 
be said that some bacterial DNA are immunogenic and capable, during host encounter 
with microorganisms, of inducing antibodies to unique sites on these molecules (Grudier 
et al., 1998). Further, chemically or physically modified DNA, or helical structures that 
differ significantly from the B-DNA helix are much stronger immunogenic stimuli than 
native DNA and most of the antibodies induced by modified DNA do not react or react 
weakly with the unmodified DNA. 
Free Radicals 
Free radical is a chemical species formed by homolytic fission of a covalent 
bond, or by the loss or addition of a single electron from or to a normal molecule. Free 
radicals possess an unpaired electron in outer shell of the molecule which accounts for 
their short half lives and high reactivity. In order to attain stability they attack the nearby 
molecule of opposite spin and captures its electron which results in beginning of a chain 
reaction such that the attacked molecule becomes a free radical and the process 
continues. Finally leading to cellular damage (Martinez- Cayuela, 1995). The presence of 
free radical and their role in health and disease has widely been accepted into the 
biochemical and medical orthodoxy. The broad definition of free radical includes the 
hydrogen atom (one unpaired electron), most transition metals and the oxygen molecule 
itself It is now well established that free radicals and other reactive oxygen species 
(ROS) along with reactive nitrogen species (RNS) are continuously produced in vivo, 
and can damage most cellular components. Many toxic agents also generate intracellular 
oxygen radicals. In consequence, several antioxidant defence systems limit their 
damaging effects and also repair systems to prevent the accumulation of oxidatively-
damaged molecules (Sies, 1991). 
The production of free radical can either be accidental or deliberate; they are 
generally produced in cells by electron transfer reactions mediated by the action of 
enzymes or through the redox chemistry of transition metal ions. Some enzymes utilize a 
free radical at their active site in the process of catalysis, for example ribonucleotide 
reductase (Richard and Ehrenberg, 1983). Activated phagocytes also deliberately 
generate superoxide as part of their bactericidal role (Babior, 1978). The major source of 
free radicals in a cell is electron leakage from electron transport chains, such as those in 
mitochondria and in the endoplasmic reticulum, to molecular oxygen, generating 
superoxide. Flavin oxidases located in the peroxysomes also produce superoxide or 
hydrogen peroxide. The term reactive oxygen species includes not only oxygen-centered 
radicals as superoxide (O2 ~ ) and hydroxyl ion (OH ), but some non-radical derivatives 
of oxygen, such as hydrogen peroxide (H2O2), singlet oxygen ('O2), Hypochlorous acid 
(HOCl) and ozone (O3) that are involved in oxygen radical production (Weser et al., 
1990). The term reactive nitrogen species includes nitric oxide (NO), nitrogen dioxide 
(NO2), nitrous anhydride (N2O3), peroxynitrite (0N00~ ), nitrogen trioxide (NOa" ), 
nitroxyl anion (N0~) etc. 
Nitric Oxide Bioclieniistry 
Biosynthesis of nitric oxide takes place by the conversion of L-arginine to L-
citrulline (Fig. 1) catalyzed by nitric oxide synthases. The enzyme has three isoforms : 
neuronal nitric oxide synthase (NOSi), inducible nitric oxide synthase (NOS2) and 
endothelial nitric oxide synthase (NOS3). Amongst these, the first isoform purified and 
cloned is neuronal nitric oxide synthase (David et al., 1998) Constitutive NOS is calcium 
dependent and continuously present whereas inducible nitric oxide synthase is calcium 
independent and is expressed only after cytokine exposure. Based on this category nNOS 
and eNOS are constitutively expressed and require elevatated levels of Ca along with 
activation of calmodulin to produce NO for brief period of time (Bredt et al., 1992). 
Inducible NOS 
This type II NOS is induced by inflammatory stimuli e.g. cytokines or 
lipopolysaccharides and is mainly expressed in macrophages. Inducible NOS possess, 
tightly bound calmodulin. It is also reported that iNOS is not only present in activated 
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Fig. 1. Enzymatic synthesis of nitric oxide 
macrophages but its synthesis can be induced in gHal cells, liver and cardiac muscle 
(Gordge, 1998). 
Endothelial NOS 
It is constitutively expressed in endothelial lining of blood vessels and depends 
on Ca . The NO produced by eNOS diffuses into smooth muscle cell of Blood vessel 
and elicits cGMP dependent smooth muscle relaxation and thus increasing blood flow 
(Nathan et al., 1994). 
Neuronal NOS 
Neuronal nitric oxide synthase is constitutively expressed in post synaptic 
terminals of neurons and is Ca dependent. It is activated by Ca influxes caused by 
binding of neurotransmitter, glutamate, to the receptor in cell membrane, nNOS is also 
activated by membrane depolarization through opening of voltage gated Ca"*"^  channels 
(Silvia et al., 1999). 
Nitric oxide synthases utilize L-arginine, NADPH and oxygen as a substrate to 
produce nitric oxide. It is only heme iron dependent tetrahydrobiopterin H4-biopterin 
enzyme where H4 binds far away and on the wrong site of poryphyrin to act as 
hydroxylating co-factor at distal side of heme iron center (Silvia et al 1999). Other 
enzymes that use H4 biopterin are e.g. phenyl monooxygenase, tyrosine 3-
monooxygenase and tryptophan 5-monooxygenase. In these cases H4-biopterin is 
directly involved in hydroxylation of substrate, getting oxidized to H2-biopterin, which is 
again recycled to H4-biopterin by dihydropteridine reductase. Nitric oxide synthase 
enzyme in its active form is a homodimer where each subunit is composed of C-terminal 
reductase and N-terminal oxygenase domain (Fig. 2 ). It is also reported that the isolated 
oxygenase domain remain homodiameric whereas isolated reductase domain is 
monomeric indicating that the two subunits are joined by their oxygenase domains 
(Tamir et al., 1996). The oxygenase domain contains a heme group and one binding site 
for pteridine cofactor tetrahydrobiopterin and L-arginine whereas reductase domain of 
nitric oxide synthase has binding sites for one molecule of FMN, FAD, and NADPH. 
Between the reductase and oxygenase domain there is a binding site for calmodulin 
(Nathan et al., 1994). In case of nNOS and eNOS only Ca-calmodulin complex can 
activate the enzyme whereas in case of iNOS it is already bound to calmodulin and is 
fully active. Calmodulin is reported to improve electron flow fi-om NADPH to flavins 
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Fig. 2. Structure of nitric oxide synthase enzyme. 
and also facilitate electron transfer from FMN to heme. Table-2 summarizes some of the 
properties of nitric oxide synthase enzyme. 
Nitric oxide (NO) is composed of an atom of nitrogen and oxygen such that 
seven electrons from nitrogen and eight electrons from oxygen are involved to form an 
uncharged molecule (N^O). The high reactivity of nitric oxide is not due to the fact that 
it contains an unpaired electron rather NO reacts only with those biological molecules 
that have unpaired orbital electrons e.g. other free radicals or transition metal ions 
(Padmaja et al., 1993). 
The biological reactions of nitric oxide can be divided into three main path ways-
(i) Diffusion 
Nitric oxide trespasses the cell membrane by simple diffusion and reacts with 
cellular components. Once inside the cell, it may react with non-heme iron or quench 
tyrosyl radical of ribonucleotide reductase which may lead to inhibition of DNA 
synthesis (Roy et al., 1995). 
(ii) Autooxidation to form nitrous anhydride 
Nitric oxide combines with nitrogen dioxide to form nitrous anhydride. 
NO + NO2 -^ N2O3 
(iii) Reaction with super oxide to form peroxynitrite 
Reaction of nitric oxide with superoxide in biological media yields peroxynitrite 
which is not a free radical but a negatively charged species capable of reacting with 
almost all biological molecules and hence, a potent oxidant. One of the known fastest 
reactions of peroxynitrite is its combination with CO2 to form nitrosoperoxycarbonate 
adduct. 
0N00"+C02 > [ONO2 CO2"] > N03" + C02 
Nitric oxide also reacts with molecular oxygen to form NO2 in gaseous phase 
whereas in aqueous phase NO and N03~ are the final products (Goldstein et al; 1995). 
gaseous aqueous 
2NO + O2 > 2NO2 > N0" + N03~ 
The nitroxyl anion (NO") formed is also known as endothelium derived relaxing 
factor. NO can also directly interact with hypervalent complexes formed by agents such 
as H2O2 and reduce it to a lower valency state thus protecting tissue damage (Puppo et 
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TABLE 2 
Properties of NOS Enzymes 
FORM OF 
ENZYME 
Inducible 
Neuronal 
Endothelial 
M.WT. KDa 
130 
160 
134 
Ca^ -^
DEPENDENCY 
Independent 
Dependent 
Dependent 
TYPE OF 
EXPRESSION 
Induced by 
inflammatory 
stimuli 
Constitutively 
expressed 
Constitutively 
expressed 
TISSUE 
EXPRESSION 
Macrophages, 
astroc)'tes, 
hepatocytes, 
smooth muscle 
cells, epitheUal 
cells. 
Neuronal and 
skeletal muscle 
cells. 
Endothelial 
cells and 
cardiomyocytes 
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al., 1998; Kanner et al., 1991). NO is also capable of reacting with oxyhemoglobin and 
results in the formation of met-Hb and NO3" (Albina et al., 1993). 
Hb - Fe" (O2) + NO > Hb-Fe"' + N03" 
Nitric oxide indirectly interacts with biological molecules through the formation 
of a powerful oxidant i.e. peroxynitrite, which is governed by relative amounts of NO 
and super oxide produced. 
NO + O2" > ONOO" 
An intracellular source of ONOO" is mitochondria where aerobic respiration 
results in the production of superoxide as well as NO. The peroxynitrite formed can also 
influence protein and enzyme function. This occurs by nitration of tyrosine residues thus 
contributing to pathological dysfunction (Silvia et al., 1999). The formation of 3 
nitrotyrosine is contributed by many nitrogen oxide species such as peroxynitrite, 
nitrogen dioxide, nitrous acid, nitronium ion etc. This nitrated product is found in many 
disease states as e.g. chronic inflammation, atherosclerosis, lung injury etc (Beckman et 
al., 1993; Beckman et al., 1994). 
Peroxynitrite (0N00~), a short lived specie with ti/2 < 1 sec, is capable of 
inflicting oxidative damage to a wide range of biological molecules viz., nucleic acids, 
lipids, thiols etc (Beckman et al., 1996). At pH 6.8 its conjugate acid ONOOH can 
diffuse through membranes and cause damage at a distance from its site of synthesis. 
Role of Nitric Oxide in DNA Damage 
Nitric oxide mediates DNA damage by three mechanisms: 
(a) Formation of nitrosoamines. 
(b) Inhibition of DNA lesion repair systems which is also mediated by other genotoxic 
systems. 
(c) Modification of DNA by oxidation products of NO. 
There are many carcinogens in human food and drink and can also arise from the 
normal metaboUsm of living organisms (e.g. aflatoxins), from cooking process (e.g. in 
barbecued meat). The most important human carcinogens may be metabolites of gases in 
the air around us i.e. both nitrogen and oxygen are procarcinogens. Nitrogen is taken into 
body as nitrates, nitrites, peptides, proteins, and amino acids and its metabolites include 
higher oxides of nitrogen and peroxynitrite. Although NO is a free radical, it is probably 
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insufficiently reactive to attack DNA directly. By contrast N2O3, HNO2, ONOO" can 
nitrate and deaminate DNA and cause strand breaks and mutations (Ames et al., 1997) 
e.g. 0N00~ can induce G —> T transversions where as demination of adenine to 
hypoxanthine can result in transitions AT ->GC since hypoxanthine can pair with 
cytosine. Living organisms have therefore evolved enzymes that can remove 
deamination products of cytosine (uracil), adenine (hypoxanthine) and guanine 
(xanthine) from DNA to decrease the risk of mutagenecity (Savva et al., 1995). 
Estimates of total daily production of oxides of nitrogen in the healthy human body are 
about 1 mmole/day based on steady state levels of plasma NOa" and N02~ in subjects 
placed on diet free of these substances (Wennmalm, et al., 1994). Excess production of 
reactive nitrogen species e.g. as a result of H.pylori infection, chronic inflammation, or 
excessive consumption of NO2" rich foods may enhance the risk of gastric cancer by 
mechanisms involving formation of N-nitroso compounds and possibly also deamination 
of DNA (Oshima et al., 1981; Oshima et al, 1994; Oshima et al., 2003). Deamination 
and nitration of purine bases has been represented in (Fig. 3 ). Endogenous generation of 
reactive oxidants has been known to react with DNA (Mamett et al., 2003) 
It has also been reported that quinone derivative of catechol estrogen, which is 
produced by NO mediated oxidation may form covalent adducts with nucleophilic 
groups of DNA (Dwivedy et al., 1992). Also the catechol-estrogen adducts or complexes 
are oxidized to quinones which can reduce oxygen to generate 02~ ion or in presence of 
NO releasing compound leads to the production of ONOO" (Yumiko et al., 1998). 
Similarly polyhydroxy aromatic compounds such as pyrogallol and 1,4-
hydroquinone auto-oxidize easily to form semiquinone radicals that react with dioxygen 
to generate 02~ which in combination with NO releasing compound like SNP, DEA-NO, 
SPER-NO results in production of ONOO" responsible for DNA damage (Fig. 4) 
(Yumiko et al., 1997). It is also reported that when cells were exposed to NO it resulted 
in DNA single strand breakage. However when purified DNA was exposed to NO at 
concentrations as high as 1.0 M, single strand breaks were not observed. Nitric oxide is 
also known to protect DNA against chemistry of oxidative stress by inhibiting Fentons 
reactions of hydrogen peroxide which leads to single strand generation (Pacelli et al., 
1994). Some products of oxygen reduction such as superoxide (02~) and hydrogen 
peroxide (H2O2) are not capable of reacting directly with DNA except at levels above 
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their physiological range. Singlet states of oxygen ('O2) readily oxidize guanine, the 
most oxidizable base in DNA. Hydroxyl radical generates multiplicity of products from 
all four DNA bases e.g. OH can attack guanine at several positions and attack at position 
8 generates 8-hydroxyguanine which has many fates depending upon the environment of 
redox potential (Fuciarelli et al., 1990). Oxidation generates 8-hydroxy guanine whereas 
reduction leads to a ring opened product as depicted in (Fig. 5). Other reactive species 
cause different patterns of damage to DNA. This has been established for singlet oxygen 
(Ravanat et al., 1995; Epe, 1992; Mori et al., 1998), peroxynitrite (Yermilov et al., 1995), 
Hypochlorous acid (Whiteman et al., 1997) and nitryl chloride (Loeb et al., 1989). Hence 
it is possible to use base damage pattern observed in DNA that has been isolated from 
cells and tissues in order to gain information about which reactive species may have 
caused DNA damage in vivo e.g. DNA isolated from brains of patients with senile 
dementia of the Alzheimer type shows a pattern of purine and pyrimidine damage 
suggestive of attack by OH whereas in senile dementia of lewy body type elevations in 
deamination products, suggestive of attack by reactive nitrogen species are observed. By 
contrast in Parkinsons disease there is a selective oxidation of guanine ruling out OH as 
damaging specie (Lyras et al., 1998; Alam et al., 1997). 
Direct chemical modification of DNA is only one of several mechanisms by 
which reactive oxygen/nitrogen/chlorine species can cause mutations or promote 
carcinogenic states. Oxidation of lipids induced by reactive species can generate end 
products, such as malondialdehyde and unsaturated aldehydes that can bind to DNA to 
generate potentially mutagenic lesions. DNA polymerase and repair enzymes could be 
damaged by reactive species, decreasing the fidelity of replication and slowing the repair 
of lesions (Chaudhary et al., 1994). Attack on DNA by species such as OH, ONOO', 
NO2CI and HOCl produces a multiplicity of products. It is also reported that when 2'-
deoxyguanosine was treated with NO/ O2 mixture at pH 7.0-7.8 a novel lesion, N2-nitro-
2-deoxyguanosine was detected through RP-HPLC (Yamada et al., 2000). For the last 
three species, 8-OHdG is not one of the major products formed (Douki et al., 1995; 
Spencer et al., 1995). Indeed ONOO' and HOCl can destroy preformed 8-OHdG in DNA 
since hydroxylated guanines are more easily oxidizable than guanine itself Thus it can 
be said that 8-OH-dG levels are not always a quantitative index of oxidative attack of 
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guanine residues in DNA. They can be affected by redox state of the cell and the mixture 
of reactive species present. 
Defence Against Reactive Nitrogen Species 
It is now well established that reactive species of nitrogen in vivo and in vitro can 
damage cells, tissues, proteins, carbohydrates, lipids and DNA. The deleterious reactions 
of RNOS are partially controlled by antioxidants. There is a good evidence that 
endogenous antioxidants synthesized by aerobes e.g. SOD, catalase, GSH do not 
completely prevent damage by reactive species in vivo. Hence efficient repair systems 
are needed. Repair of the damage done to DNA by reactive species is particularly 
important as the constant assault by these species on DNA throughout long life span may 
contribute to age related cancers (Floyd, 1990; Kasai, 1997). 
(a) Physical restriction- Selective compartmentalization and physical restriction are 
important features of defence against deleterious effects of free radical e.g. the free 
radical intermediate produced in the electron transport chain are tightly coupled in 
the membrane bound enzymes and carriers. Thus protecting membrane 
polyunsaturated fatty acids from lipid peroxidation (Williams, 1985) 
(b) Control of super oxide-The enzyme super oxide dismutase (SOD) catalyses 
dismutation of O2" to H2O2. 
SOD 
02"+ O2 •" > H2O2 + ' O2 
02~ is responsible for the production of ONOO" in presence of NO. This ONOO" is a 
potent oxidant and strong DNA damaging and mutating agent. SOD enzymes are 
metalloproteins, cytosolic SOD are Zn-Cu based enzyme whereas mitochondrial SOD is 
magnesium based (Singh et al., 1994). 
Humans also obtain certain antioxidants from the diet e.g. vitamin E (a-
tocopherol) which remove free radicals by reacting directly with them non enzymatically 
(Som et al., 1983). Some of these antioxidants can be made to exert prooxidant effect in 
vivo, often by interaction with transition metal ions. This is well known that ascorbate in 
presence of iron salts induce lipid peroxidation, phenols are also known to produce pro-
oxidant effects in vitro (Rahman et al., 1989). Antioxidants may have protective actions 
not only after their absorption into the body, but even before that. The gastrointestinal 
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tract e.g. salivary and diet derived N02~ presumably react with gastric acid to produce 
HNO2 which decomposes to oxides of nitrogen. Nitrous acid can deaminate DNA bases: 
guanine is most sensitive, followed by adenine. Several phenolic compounds are 
powerful inhibitors of deamination, much more than ascorbate (Oldreine et al., 1998). 
Hence phenols in fruits, vegetables, wines, tea and other beverages could conceivably 
exert a gastroprotective effect in situations of excess production of reactive nitrogen 
species e.g. consumption of food rich in NO2'. Unabsorbed iron and phenolic compounds 
end up in faeces, since colon is hypoxic; faces incubated under aerobic conditions 
generate reactive oxygen species at a high rate. The ability of dietary phytates and 
phenolics to pass unabsorbed through colon where they chelate iron and scavenge 
reactive oxygen, nitrogen and chlorine species. This may be beneficial in cases where 
transient rise in intra colonic oxygen tension occurs or inflammation of colon takes place 
(Babbs, 1990). The conclusions that can be drawn are-: 
(1) There is no evidence that p-carotene decreases oxidative DNA damage in humans 
(Von, Poppel, et al., 1995). 
(2) Vegetables may decrease oxidative DNA damage by mechanisms unrelated to 
their content of P-carotene or vitamins E and C. (Verhagen et al., 1995). 
(3) Dietary antioxidants may be beneficial only upto a point. 
(4) It has been demonstrated that metallothionein inhibits peroxynitrite-induced 
DNA and lipoprotein damage Metallothionein functions as an antioxidant that 
protects against oxidative DNA, protein and lipid damage induced by superoxide 
anion, hydrogen peroxide, hydroxyl radical and nitric oxide. It was shown that 
DNA damage by 3-morpholinosydnomine was prevented by metallothionein and 
SOD where as damage caused by peroxynitrite was prevented by metallothionein 
only (Cai et al., 2000). 
(5) Antioxidant and prooxidant activities of flavanoids, which are diphenyl propane 
derivatives, indicate that they have both deletrious as well as beneficial effects. It 
has been reported that most of the tested flavonoids except one having 
orthotrihydroxy group in either the P ring (epigallocatechin gallate) or the A ring 
(e.g. quercetagetin) act as antioxidants, i.e they inhibit peroxynitrite-mediated 
formation of 8-nitroguanine in calf thymus DNA (Oshima et al., 1998; Yen and 
Lai, 2002) 
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DNA Repair 
When cells are exposed to species like reactive oxygen and nitrogen radicals, 
large spectrum of DNA lesions are produced, therefore, an immediate response to DNA 
damage is its repair. In mammalian cells these pathways are poorly characterized and 
despite the abundant information flowing from facile combination of biochemical and 
genetic approaches in E.coli the function of mammalian counterparts of the microbial 
enzymes is only hypothesized or extrapolated from microbial models. The nucleotide 
excision repair system of E.coli Uvr ABC although not pivotal for handling oxidative 
damage in contrast to its crucial role in repair of structurally distorting lesions such as 
pyrimidine photodimers and some carcinogen adducts (Sancar and Tang, 1993) 
nevertheless, acts as a secondary defence against oxidative damage. On the other hand, 
recombination mechanisms can in principle repair any DNA lesion provided that an 
intact copy of the affected region resides in the same cell (West, 1992). Recombination is 
likely to be crucial for at least two classes of oxidative damages, i.e. interstrand cross 
links and double strand breaks. 
Besides these repair systems, certain enzymes such as DNA glycosylases are 
important in initiating repair by hydrolyzing the base-sugar (N-C glycosylic) bond of 
modified or incorrect base to generate a basic apurinic site (Sancar and Sancar, 1988). 
Endonuclease III of E.coli is a thymine glycol glycosylase that specifically cleaves 
duplex DNA damaged by X-rays, UV light, osmium tetraoxide and acidic pH. Thymine 
glycol and dihydrothymine were the first identified substrates for the endonuclease III 
glycosylase (Demple and Linn, 1980). Possible counterparts to E.coli endonuclease III 
have been found in other organisms. Some other glycosylases include formamido 
pyrimidine glycosylase, hypoxanthine-DNA glycosylase, 5-hydroxymethyl uracil and 5-
hydroxymethyl cytosine DNA glycosylase. It has been suggested that the last two 
glycosylases exist to maintain 5-methyl cytosine in DNA of vertebrate cells in the face of 
free radical damage. The repair enzymes identified so far can be used as a gentle probe 
for a more complete understanding of oxidative damage to DNA under physiological 
conditions. 
Autoimmunity 
Autoimmune diseases are caused by failure to distinguish between host and 
foreign antigens. There is no single theory or mechanism that can adequately explain all 
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features of autoimmune diseases. One theory is to consider the wide spectrum of 
autoimmune diseases as mosaic of autoimmunity with many pieces 
(i) T-helper/T-suppressor cell imbalance 
The immune system is controlled mainly by regulatory influence of T-
lymphocyte subsets. In normal individuals the ratio of T-helper to T-suppressor 
in peripheral blood is 2:1 whereas in almost all of the autoimmune disease the 
ratio increases to 15:1, particularly during active phase of disease. (Raviranjan et 
al., 2001). hi most cases there is significant decrease in T-suppressor cell number 
and activity which accounts for increased TH/TS ratio, 
(ii) Genetic factors 
Autoimmune disease shows highly significant familial predisposition. The 
involvement of genetic factors has been linked to the human lymphocyte antigen 
(HLA) particularly HLA-DR locus. The HLA genes function as secondary genes 
to allow expression of specific autoantibody or respective disease state (Harley et 
al., 1998). 
(iii) Hormonal factors 
Autoimmune disease are more common in females than in males with a ratio of 
10:1. There is evidence to support the fact that sex related factors are involved in 
the pathogenesis of SLE (Moinuddin et al., 1998). It is also reported that 
testosterone and thymic hormones enhance CD8^ T cell receptor function (Lahita 
and Kunkel 1984) whereas estrogen may suppress this function (Talal and 
Ahmad 1987). 
(iv) Polyclonal B cell activation 
Polyclonal B-cell activation may be one of the mechanisms responsible for over 
all activation of B-cell and production of autoantibodies in certain autoimmune 
diseases (Hahn, 1993). B-cell hyper-responsiveness and poly- clonal activation 
are present in SLE. In autoimmune prone individuals, B-cell are hyper-responsive 
to polyclonal activators and undergo initial activation followed by expansion 
including that of the autoreactive clones under the influence of exogenous or 
endogenous polyclonal activators (Theofilopoulos, 1995). 
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Classification of Autoimmune Diseases 
Autoimmune diseases in humans are broadly divided into two categories. 
a) Organ-specific autoimmune disease. 
b) Systemic autoimmune diseases. 
In organ specific autoimmune diseases the immune response is directed to a 
target antigen unique to a single organ or gland so that manifestations are largely limited 
to that gland. Whereas in systemic autoimmune diseases the response is directed towards 
a broad range of target antigens and involves a number of organs and tissues. These 
diseases reflect a general defect in immune regulation that results in hyperactive T cells 
and B-cell. Tissue damage is wide spread (Richard et al., 2000) 
Systemic Lupus Erythematosus 
Systemic Lupus erythematosus (SLE) is a disease of unknown etiology in which 
tissues and cells are damaged by pathogenic autoantibodies and immune complexes. 
Ninety percent cases are in women, usually of child bearing age but children, men and 
the elderly can also be affected. In the United States the prevalence of SLE in urban 
areas varies from 15-50 per 100,000 populafion. It is more common in blacks than in 
whites. Hispanic and Asian population are also susceptible. 
SLE results fi^om tissue damage caused by pathogenic subset of autoantibodies 
and immune complexes. The abnormal immune response is due to polyclonal and 
antigen-specific T and B lymphocyte hyperactivity and its inadequate regulation. 
Evidence for genetic predisposition includes increased concordance for disease in 
monozygotic (24 to 58%) compared to dizygotic (0 to 6%) twins. Studies of association, 
linkage and genome scarming show complex genetic susceptibility (Austin et al., 1999). 
Most people with homozygous deficiencies of early component of complement (Clq, 
C2, C4) have SLE or similar disease (accounting for 5% of SLE patients), suggesting 
that these genes are major predisposing factors. Most patients must inherit multiple 
susceptibility genes, and probably experience environmental stimuli as well to develop 
clinical disease. A defective or deleted class III allele, C4AQO, is the most common 
genetic marker associated with SLE in many ethnic groups (40-50% of patients 
compared with 15% of healthy controls). One extended haplotype, 
B8.DR3.DQw2.C4AQO predisposes to SLE in populations with Northern European 
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heritage. SLE is associated with HLA-DR2 or DR3 in many groups and single-gene 
association occurs between HLA class II (especially DQp) and autoantibodies that 
associate with clinical subsets of lupus (Harley et al., 1998). Genome scanning from 
several laboratories has shown two regions of chromosome I that link to disease in 
sibpairs or multiplex families. One region, Iq23 contains the FcyRII A gene; the other 
Iq41-42, contains poly[ADP-ribosyl polymerase (PARP)] which may be another 
predisposing gene that plays a role in DNA repair and apoptosis (Austin et al.,1999 ). 
Other resuhs of genome scanning suggest that at least 10 other regions on various 
chromosomes in addition to HLA alongwith two regions on chromosome I participate in 
susceptibility (Hahn, 1998). 
Environmental factors that cause flares of SLE are largely unknown, with the 
exception of UV-B (sometimes UV-A). As many as 70% of patients are photosensitive, 
other factors such as injected alfalfa sprouts, and chemicals, such as hydrazines, have 
been implicated, searches for viral/retroviral disease inducers have been inconclusive. 
Although some drugs can induce lupus like disease, there are notable clinical and 
autoantibody differences between drug induced and spontaneous lupus (Quismoro, 
1997). 
Abnormal immune responses permit sustained production of pathogenic subsets 
of autoantibodies and immune complexes. Some autoantibodies, such as anti-DNA can 
bind to tissue via charge or cross reactivity or in immune complexes, and cause 
complement-mediated damage (Hahn, 1998). Some anti DNA and anti-RNP antibodies 
can bind and enter living cells, altering their function. Other autoantibodies cause 
damage by direct binding to cell membranes (erythrocytes, platelets) that cause those 
cells to be phagocytized and destroyed. T-cell help is critical to development of full-
blown disease, cells of CD4"^ CDg", CD4'CD8"^  and CD4"CD8~ phenotypes all help 
autoantibody production in SLE. The structure of antigens that stimulate autoantibodies 
is under investigation. Some are clearly derived from self antigen like nucleosomes, 
ribonucleoprotein, erythrocyte and lymphocyte surface (Table 3) Some may be from 
external environment and mimic self (e.g. components of vesicular stomatitis virus 
mimic peptides in Sm antigen (Kimberley, 1994). Therefore it can be said that some 
individuals are genetically predisposed to SLE. Under the influence of multiple genes. 
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TABLE 3 
Principal Antinuclear Antibodies in Systemic Lupus Erythematosus 
SPECIFICITY 
Native DNA 
Denatured DNA 
Histones 
Sm 
UlRNP 
SS-AR/Ro 
SS-B/La 
Ku 
PCNA/Cyclin 
Ribosomal RNP 
TARGET ANTIGEN 
dsDNA 
ssDNA 
H1,H2A,H2B,H3,H4 
Sn RNP proteins, B , B\ D, E 
Sn RNP proteins, A, C, 70K 
60 Kd and 52 Kd proteins, 
complex ed with Yl- Y5 
RNA 
46 Kd protein complexed 
with various RNA 
86 Kd and 66 Kd protein 
36 Kd protein 
38Kd,16Kd, andlSKd 
phosphoproteins, associated 
with ribosomes 
FUNCTION 
Genetic 
information 
Genetic 
information 
Nucleosome 
structure 
SpUceosome 
component, RNA 
processing 
SpHceosome 
component, RNA 
processing 
Unknown 
Regulation of 
RNA 
polymerase-III 
DNA binding 
Auxiliary protein 
of DNA 
polymerase 
Protein synthesis 
FREQUENCY 
IN SLE ( % ). 
40 
70 
70 
30 
32 
35 
15 
3 
10 
10 
Source : Tan, E,M. (1989) 
24 
possibly triggered by environmental challenges and highly influenced by sex, they may 
develop a number of different clinical syndromes that fulfill diagnostic criteria for SLE. 
Clinical Manifestations and Differential Diagnosis 
The presence of characteristic antibodies confirms the diagnosis of SLE, ANAs 
are the best screening test. If the test substrate contains human nuclei more than 95% of 
the lupus patients will be positive. Positive ANA test is not specific for SLE (Boumpas et 
al., 1995). ANAs occur in some normal individuals (usually low titre). The frequency 
increases with aging, other autoimmune diseases, viral infections, chronic inflammatory 
process. Moreover, several drugs induce anti-nuclear antibodies. Therefore a positive 
ANA test supports the diagnosis of SLE but is not specific, the negative test makes 
diagnosis unlikely but is not impossible. Antibodies to double-stranded DNA (dsDNA) 
and to Sm are relatively specific for SLE (Hahn, 1998). High serum level of ANAs and 
anti ds-DNA and low levels of complement usually reflect disease activity, especially in 
patients with nephritis. Total functional hemolytic complement (CH50) levels are most 
sensitive measure of complement activation. Very low levels of CH50 with normal levels 
of C3 suggest inherited deficiency of a complement component, which is highly 
associated with SLE and with negative ANA (Hahn, 1998).Hematologic abnormalities 
include anemia, leukopenia, lymphopenia, thrombocytopenia (Boumpas et al., 1995). 
Urine analysis should be performed and serum creatinine levels should be 
measured periodically in patients with SLE. With active nephritis, the urine analysis 
usually shows protinuria, hematuria, and cellular and granular casts (Stone et al., 1998). 
Drug Induced Lupus 
Several drugs including procainamide, hydralazaine, isoniazid, chlorpromazine, 
D-penicillamine, practolol, methyldopa, interferon-a etc cause a syndrome like SLE 
(Schur, 1993). The syndrome is rare with all but procainamide. There is genetic 
predisposition to drug induced lupus. Partly determined by drug acetylation rates. 
Procainamide induces ANA in 50 to 75% individuals within a few months, hydralazaine 
induces ANA in 25 to 30%). Between 10 to 20%) of ANA positive individuals develop 
lupus-like symptoms (Cowchock, 1998). Most common are systemic complaints and 
arthralgias, polyarthritis and pleuropericarditis. Renal and CNS involvement are rare. All 
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patients have ANA and most have antibodies to histones. Antibodies to ds DNA and 
hypocomplementemia are rare (Raeder et al., 1985). This is a helpful point in 
distinguishing drug induced from idiopathic lupus. 
Role of Nitric Oxide in SLE 
Nitric oxide (NO) is a mediator of a variety of normal physiologic functions 
including maintaining vascular tone and also functions as a neurotransmittor. NO 
modulates the production of Thl cytokines and, depending on the specific immune cell 
type, may induce or inhibit apoptosis (Taylor-Robinson et al., 1994). A number of 
inflammatory mediators in murine models stimulate NO production e.g. 
lypopolysaccharide, cytokines including interleukin-12, and tumor necrosis factor a also 
up regulate iNOS resulting in release of NO. In murine models of lupus, NO is a 
mediator of disease, as blocking NO production prevents or delays disease 
manifestations (Oates et al., 1997). In human autoimmune disease, studies using different 
measures of NO revealed increased levels of NO production in rheumatoid arthritis, 
ulcerative colitis and to more extent lupus compared to healthy controls. It was reported 
that expression of iNOS was increased in the kidneys of patients with lupus. Increased 
levels of serum nitrate/nitrite (N/N metabolites of NO) were found in patients with SLE 
(Kashem et al., 1996). These results suggest that measure of NO production, although 
not specific for lupus, may be useful indicators of lupus disease activity in individual 
patients followed over time. It has been postulated that similar to animal models, 
monocytes and tissue macrophages are primary cells that over produce NO in lupus and 
that local production of NO occurs in kidneys by infiltrating macrophages (Gilkeson et 
al., 1999). Although local NO production appears deleterious in lupus, productions of 
NO in other disease states may be beneficial. Studies in animal models of multiple 
sclerosis and inflammatory bowel disease suggest that the local production of NO may 
be beneficial by inducing apoptosis of inflammation cells and by turning off production 
of certain cytokines (Mc-Cafferty, 1997). It has also been reported that blocking nitric 
oxide production rather than after clinical presentation was effective in MRL-Lpr mice. 
This difference in efficacy between early and late therapy may reflect that: 
(a) Once inflammation has initiated, multiple pathways in addition to those mediated by 
NO are responsible for its progression. 
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(b) NO is an important mediator in early, acute but not in chronic inflammation. 
(c) While reducing NO production may result in reduced inflammation (Oates et al., 
1997) 
Also to relate the role of NO in SLE its site of production and quantum is of 
relevance. Patients with SLE showed upregulation of iNOS in normal appearing vascular 
endothelium. These endothelium also over-express the vascular adhesion molecules 
ICAM-1, E-Selection and VCAM (Belmont et al.,1994). SLE is a prototypical 
autoimmune disease in which over production of nitric oxide (NO) has been implicated 
in its pathogenesis. Many studies have indicated a correlation between serum nitrate and 
nitrite (NOx) levels and the disease activity. But this measure can be falsely elevated by 
exogenous dietary and medication sources of NOx- These variables can make NOx a less 
reliable tool for studying the role of NO in SLE. Peroxynitrite, a by product of NO and 
superoxide, nitrates tyrosine moieties. The resulting 3-nitrotyrosine (3NT) serves as a 
long-term indicator of NO-mediated protein modifications that is not affected by 
exogenous sources of NOx or serum thiols (Sampson et al., 1996). It was correlated that 
for these reasons serum 3NT levels were related to lupus disease activity more 
significantly than serum NOn. It was found that patients having active lupus nephrites 
had higher levels of serum 3NT than those without renal disease. Immuno-histochemical 
analysis of renal biopsies from subjects with active proliferating lupus nephritis revealed 
normal expression of iNOS Therefore, it could be concluded that over production of NO 
may play a pathogenic role in SLE and lupus nephrites and that the serum 3NT may be a 
useful tool for studying contributions of NO to the pathogenesis of SLE (Oates et al., 
1999). 
Treatment 
There is no cure for SLE. Therefore treatment is symptomatic and is planned to 
control acute flares and maintain strategies in which symptoms are suppressed. Basically 
treatment is done on the basis that-
(a) Patients have mild disease with no life threatening manifestations. 
(b) Life threatening, severely disabling manifestations of SLE. 
Approximately 25% of patients have mild disease; therefore these patients are 
managed without glucocorticoids. NSAID (nonsteroidal anti-inflammatory drugs) are 
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prescribed along with salicylates (Kimberly, 1994) to improve arthralgias, arthritis, 
myalgias, fever etc. For treating dermatitis and fatigue, antimalarials are used e.g. doses 
of 400 mg hydroxychloroquinone may improve skin lesions. They are advised for regular 
opthalmologic examinations. Other therapies include sunscreens (SPF > 1.5), tropical, 
intralesional glucocorticoids, vetinoids, dapoones etc may be given. Recent studies 
indicated the beneficial use of dihydroepiandrosterone to lower disease activity in 
patients with mild SLE (Ward et al., 1995). 
Life threatening and severely disabling manifestations of SLE that are responsive 
to immunosuppression should be treated with high doses of systemic glucocorticoids (1 
to 2 mg/kg/day).When disease is active, glucocorticoids should be given every 8 to 12 hr. 
After the disease is controlled the dose is tapered as rapidly as the disease permits 
(Tumlin, 1999). The undesirable effects of chronic glucocortiocoid therapy include 
cashingoid habitus, weight gain, hypertension, infection, hirsutism, osteoporosis, 
glaucoma, insomnia, psychosis etc. 
The uses of cytotoxic agents such as azathioprine, chlorambucial, 
cyclophosphamide, methotrexate etc are beneficial in controlling active SLE and 
reducing use of steroidal drugs. For patients with lupus nephritis less renal failure and 
better survival is maintained by combining cyclophosphamide with glucocorticoids. 
Among cytotoxic agents cyclophosphamide is most toxic and most effective (Ward et 
al., 1995). Azathioprine is least toxic and the recommended doses are 2 - 3 mg/kg/day. 
The undesirable side effects of cytotoxic drugs include bone marrow suppression, 
increased infection, irreversible ovarian failure, hepatotoxicity, bladder toxicity etc. 
(Werthetal., 1997). 
Cancer 
Unlike free living cells that compete to survive, the multicellular organisms are 
committed to collaboration. Any mutation that gives rise to selfish behavior by 
individual members of the cooperative will jeopardize the future of whole organism. 
Mutation, competition, and natural selection operating within the population of somatic 
cells are best ingredients of cancer. It is the disease in which individual mutant cells 
begin by prospering at the expense of their neighbours but in the end destroy the whole 
cellular society and die. Cancer cells are defined by two heritable properties. 
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(1) Reproduce in defiance of the normal restraints 
(2) Invade and colonize territories normally reserved for other cells. 
Cancers are classified according to the tissue and cell type from which they arise. 
Cancers arising from epithelial cells are termed as carcinomas. Those arising from 
connective tissues or muscle cells are termed sarcomas. Cancers derived from 
hemopoietic cells and from nervous system are termed as leukemia's. 
When a cancer has metastasized its origins can usually be traced to a single 
primary tumor, arising in an identified organ and presumed to be derived by cell division 
from a single cell that has undergone some heritable change that enables to out grow its 
neighbours. One type of demonstration comes from analysis of the cellular DNA. It was 
found that in almost all patients with chronic myelogenous leukemia e.g. the leukemic 
white blood cells are distinguished from normal cells by a specific chromosomal 
abnormality known as Philadelphia chromosome (Fearon et al., 1987). 
This Philadelphia chromosome is created by translocation between long arms of 
chromosome 9 and 22. DNA at the site of translocation when cloned and sequenced, was 
found to be identical in all the leukemic cells in any given patient, but differs by few 
hundred or thousand base pairs from one patient to other (Groffen et al., 1984). 
Cancer has multifactorial etiology which includes both genetic and environmental 
factors (Gourley et al., 1992). Among the environmental factors, consumption of tobacco 
in various forms (e.g. smoking, chewing) is the major cause of cancer of lungs, larynx, 
mouth, pharynx, bladder, pancreas etc. Alcohol consumption is associated with cancer of 
esophagus, liver and rectum (Eskelson et al., 1993). Dietary factors such as high fat diet, 
beef consumption, food additives, and contaminants have also been related to cancer 
(Ames, 1983). 
Studies indicate that most of these exogenous carcinogens act via production of 
reactive oxygen or reactive nitrogen species. Thus reactive oxygen/nitrogen species 
produced exogenously as well as endogenously are known to play an important role in 
the initiation and promotion of multistage carcinogenesis (David et ah, 1998, Marietta, 
1988). 
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Role of Reactive Nitrogen Oxide Species in Cancer 
Cancer can be defined as malignant transformation of a cell or group of cells, 
which due to its multifactorial etiology involves both genetic and environmental factors 
(Hussain et al., 2003) Among the environmental factors the RNOS are generated both in 
the environment and pathophysiologically in mammals and induce many direct or 
indirect reactions mediated by NO leading to modulation/damage to biological 
molecules. Therefore, it can be said that RNOS has both protumor as well as antitumor 
effect. 
Anti Tumor Effect 
Nitric oxide (NO) acts as an immune effector generated by iNOS in 
macrophages, neutrophils etc. hi large quantities it kills or inhibits growth of many 
pathogens and block viral respiration. It also up regulates tumor suppressor p-53 gene 
(David et al., 1998). NO donors are capable of inhibiting angiogenesis, metastasis and 
tumor growth. Nitric oxide also inhibits DNA damage mediated by ROS via Fenton's 
chemistry besides inhibiting hydroxylation reactions (Miles et al., 1996). NO is reported 
to have tumor killing activity against many tumors. Since high risk carcinogenic sites are 
those exhibiting prolonged expression of iNOS during chronic inflammation. NO 
generated from macrophages, Kpuffer cells and NK cells are capable of inhibiting 
rephcation alongwith antitumor effect in the target cells (Kurose et al., 1993; Xio et al., 
1995). Murine embryonic liver cells, BNL CL.2 are capable of expressing iNOS in 
response to IFNy thus accumulating NO. 
In humans few tumors are caused by viruses e.g. liver cancer is caused by 
hepatitis B-virus, cervical cancer by human papilloma virus, adult T cell leukemia by 
human T-cell leukemia virus. Interferon y is particularly important in limiting the spread 
of certain viral infections and capable of expressing iNOS. Increased concentration of 
NO in or near the target cell may act as tumoricidal since NO is capable of eliminating 
intracellular pathogens and blocking viral replication (Pipili-Synetos et al., 1995). Nitric 
oxide is capable of protecting cell from apoptosis or mediating apoptosis depending upon 
the cell type. NO protects rat ovarian follicles from atretic generation on one hand while 
on the other it induces apoptosis in tumor cells like in mastocytoma, sarcoma, melanoma 
etc. (David et al., 1998; Fadeli et al., 2003). NO is also reported to protect tissue from 
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peroxide mediated damage by scavenging metallooxospecies which are formed by 
oxidation of metal species or metal oxygen species by H2O2 (Gorbunov et al., 1995). It 
has also been reported that animal subjects having tumorous growth acquire the ability 
through which their tumor tissues suppress the expression of iNOS and thus reduce the 
concentration of NO (Gardner et al., 1995; Lejeune et al., 1994). Tumor growth is 
enhanced by accelerated angiogenesis by down regulating the production of vascular 
endothelial growth factor which is the mediator of angiogenesis. NO is also capable of 
suppressing metastasis by reducing intracellular stores of GSH or by blocking the 
adhesion of tumor cells to venular side of microcirculation (Kong et al., 1996). It has 
also been reported that NO produced in vasculature of brain limits the spread of colon 
cancer to brain. Liver endothelial cells produce NO which curbs the metastasis of 
melanoma cells to lungs. Though excessive production of NO is associated with tissue 
injury, it has been reported that endothelial NO production plays protective role in 
microvasculature (Claney et al., 1995). NO is also reported to inhibit platelet aggregation 
and it reduces platelet adhesion to endothelial monolayers. The defensive properties 
accounting for beneficial effect of NO in IL-2 induced injury include protection against 
tissue injury in myocardial ischemia reperfusion and adult respiratory distress syndrome 
(Roissaint et al., 1993; Lefer, 1992). It is also reported that when cells were exposed to 
NO it resulted in DNA single strand breaks. However, when purified DNA was exposed 
to NO at concentrations as high as 1.0 M single strand breaks were not observed 
(Nguyen et al., 1992; Routledge et al., 1993). 
Protumor Effect 
Carcinogenesis can be defined as a malignant transformation of a cell or group of 
cells. This process can be divided broadly into two stages - initiation and promotion. The 
initiation phase involves an irreversible modification of the genetic material of the cell 
caused by single exposure to any carcinogenic agent where as promotion requires 
multiple exposure to the promoter to alter gene expression and produce a tumor (Lefer, 
1992). The reactive oxygen species are generated both physiologically and 
pathologically in mammals and induce many kind of cellular damage including DNA 
damage (Ames et al., 1993; Oshima et al., 2003). Since DNA plays a central role in 
information transfer attention has focussed on oxidative damage as significant source of 
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mutations that lead to cancer and other human pathologies (Ames, 1989). The possible 
role of ROS modified human DNA in cancer has been identified from studies in our lab 
and it has been found that the binding of circulating antibodies in cancer sera was much 
stronger with ROS - modified DNA than native DNA. The ROS modified DNA has been 
shown to be a better inhibitor of naturally occurring antibodies in majority of cancer 
patients than native human DNA (Saba et al., 1999), reiterating the enhanced recognition 
ofROS-DNA. 
Nitric oxide, a paramagnetic diatomic and uncharged molecule, with an unpaired 
electron and therefore highly reactive radical with half life of 2 to 30 sec. Production of 
NO has been linked to endogenous carcinogenesis (Silvia et al., 1999). Induction of 
apoptosis by NO has also been observed in culture of macrophages and pancreatic P-
cells. Macrophages exposed to nitric oxide exhibited typical morphology and showed 
DNA fragmentation indicating apoptotic cell death (Nicotera et al., 1995). NO also 
induced cell death and showed toxic effects in two different cell lines viz (CH0-AA8) 
Chinese hamster ovary cells and (TKG) human lymphoblastoid cells, highlighting the 
role of NO in the onset of mutagenesis and cell death and the involvement of these 
process in cancer and inflammatory disease (Stopper et al., 1999). NO also showed 
genotoxic effects by abolishing cell growth which is a valuable parameter sensitive to 
different kinds of damage e.g. membrane damage, energy depletion, organelle damage 
and enzyme release. 0N00~ is short lived t Yi <1 sec and is capable of oxidative damage 
of wide range of biological molecules e.g. nucleic acids, lipids, thiols, etc. (Beckman, 
1994). At pH 6.8 its conjugate acid ONOOH can diffuse through membranes and cause 
damage at a distance from its site of synthesis (Maria et al., 1997). Sensitive to apoptosis 
gene (SAG) protein, a novel Zinc RING finger protein is redox responsive and has been 
reported to protect mammalian cells from apoptosis. The sulphahydryl group of cystein 
in SAG directly reacts with peroxynitrite to prevent DNA damage. 
It is well known that solid tumors require tumor angiogenesis for their growth i.e. 
the tumorous cells should be well supplied with oxygen, nutrients and growth factors, 
besides this an important feature of malignancy is enhanced vascular permeability which 
is regulated by endothelial cell production of vasoactive substances. The endothelial cells 
synthesize NO by eNOS which helps in vascular permeability and relaxation (Angard, 
1994). Various tumors overexpress NOS (Thomsen et al., 1994; Thomsen et al., 1995). A 
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study between the relationship of malignancy and eNOS expression in endothehal ceils 
of tumor vessels showed that astiocytic tumor vessels possess higher level of nitric oxide 
production than do normal vessels and found that there was significant correlation with 
the proliferative potential and eNOS expression in tumor vessels (Iwata et al., 1999). 
Several studies have shown that NO and its reactive derivatives i.e ONOO" were found 
to be elevated in infection and inflammation and plays important role in carcinogenesis 
(Oshima et al., 1994; Wisenman et al., 1996). It has been found that carcinogenic effect 
of NO may be due to its cytotoxic potential which lead to reduced cell viability (Stopper 
etal., 1999). 
Oxidative stress mediate DNA damage by the formation of ONOO". It was 
confirmed that DNA strand breaks were generated when plasmid DNA was incubated 
with NO"donor compound and polyhydroxy aromatic compound. On autooxidation 
polyhydroxy aromatic compound produce O2 ~ (superoxide). Simultaneous generation of 
O2" and NO leads to formation of ONOO", similarly catechol-estrogens generate ONOO" 
resulting in DNA damage (Yumiko et al., 1997). 
Nitrosative stress leads to the formation of nitrosamines e.g. RNOS generated 
from acidic nitrite is potentially carcinogenic in stomach (Correa et al., 1975; Lintas et 
al., 1982) Nitrosamines are formed under conditions of inflammation which can lead to 
cancer (Oshima et al., 1994). It has also been demonstrated that sufficient nitrosative 
stress is present in vivo in some conditions which leads to the formation of nitrosamines 
that are highly carcinogenic (Liu et al., 1992). NO also enhances tumor production by 
increasing production of PGE2, a prostaglandin which increases the vasculature and thus 
angiogenesis (Inano and Onoda, 2003) . Furthermore tumor growth is supported by 
uptake of nutrients (Noguchi et al., 1996). Cells lacking Cu, Zn-SOD are reported to be 
more susceptible to NO and ONOO" (Lin et al; 1995). 
NO inhibits ribnucleotide reductase which results in impaired DNA synthesis as 
deoxyribonucleotides are no more available (Lepoivre et al., 1994). Since ONOO~causes 
DNA breaks, this leads to activation of poly(ADP-ribose) polymerase to repair damaged 
DNA (Zhang et al., 1994). The activated PARP transfers about 100 ADP ribose moieties 
from NAD^ to nuclear proteins e.g. histones and PARP itself (Szabo et al., 1996). ADP 
ribose polymers thus formed are degraded by glycohydrolases followed by NAD"^  
resynthesis which is a futile cycle and depletes ATP (Szabo et al., 1996). 
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Treatment 
Treatment for cancer can be broadly divided into two categories. 
(a) Primary cancer treatment (Surgery and Radiation) 
(a) Systemic cancer therapy 
(a) Primary cancer treatment - Most cancers present initially are localized tumor 
nodules and cause local symptoms. Depending upon type of cancer, initial therapy may 
be directed locally in the form of surgery or radiation.. Surgical excision or local 
radiation (or both) is the treatment of choice for a variety of potentially curable cancers 
including most gastrointestinal and genitourinary cancers, central nervous system tumors 
and cancers arising from breast, thyroid or skin along with most sarcomas (Deamley, 
1999). 
CT and MRI play an increasingly important role in non - invasive tumor staging 
(De Whirst, 1997). Based on the results of prospective clinical trials, positron emission 
tomography (PET) appears to be more sensitive method than traditional method with CT 
scanning. PET has also been shown to improve detection of recurrent disease for the 
purpose of second look laprotomy and debulking in colon cancer patients with rising 
levels of carcinoembryonic antigen (CEA). A monoclonal antibody against CEA labeled 
with technitium Tc99m (arcitumomab, CEA scan) is now approved for imaging of 
cancers with increased levels of CEA and has been found to be more sensitive and 
specific than CT scan (Pieterman 2000). Surgery may also play an important role in the 
treatment of selected patients with limited metastatic cancer. For certain tumor sites 
complete surgical removal of tumor can be disfiguring, disabling or unachievable and 
under these circumstances primary local therapy with ionizing radiation may prove to be 
the treatment of choice (Paszat, 1998). Well-oxygenated tumors are more radiosensitive 
than hypoxic tumors since they are bulky, implying a potential synergistic role of 
surgical debulking prior to radiotherapy. Radiation therapy is normally delivered in 
fractionated fashion over 4-6 weeks. This method has radio biologic superiority by 
permitting time for recovery of normal host tissues from sub lethal damage during 
treatment (Thomas, 1999). For most tumor types, there is a sigmoid curve of increasing 
rate of control of local tumor with increasing radiation dose. Radio sensitive tumors 
usually exhibit radio - sensitivity over the dose range of 3500-3000 cGy (Recht, 2001). 
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(b) Systemic Cancer Therapy- Use of cytotoxic drugs, hormones, antihormones and 
biologic agents has become a highly specialized and increasingly effective means of 
treating cancer (Kaye, 1998) while most anticancer drugs are used systematically, there 
are selected indications for local or regional administration. Regional administrate 
involves direct infusion of active chemotherapeutic agents into the tumor site (e.g. 
intravesical therapy for bladder cancer, intraperitoneal therapy for ovarian cancer etc. 
(Childs, 2000). In some instances e.g. Hodgkin's disease, breast cancer, lung cancer, 
optimal therapy may require a combination of therapeutic resources e.g. radiation plus 
chemotherapy, rather than either modality alone (Diel, 1998; D' Angelica et al., 1997). 
Objective of the Study 
Free radicals are produced in living cells both through endogenous as well as 
exogenous pathways. These may include oxygen as well as nitrogen radical species. 
Nitrogen free radicals include nitric oxide and its derivatives which are capable of 
causing DNA damage both through oxidative as well as nitrosative means which could 
be one of the factors leading to inflammatory diseases, autoantibody production, 
increased mutagenecity and carcinogenesis. 
In the present study human placental DNA is purified free of proteins and single 
stranded DNA and subjected to modification by the synergistic action of SNP ( a NO 
donor) and Pyrogallol (a polyhydroxy aromatic compound). The modified DNA is 
characterized by various techniques like Spectroscopy, thermal denaturation studies, 
simple and alkaline gel electrophoresis and quenching studies. Antibodies against the 
modified DNA are induced in experimental animals and the binding characteristics and 
specificity of the induced antibodies is analysed by direct binding and competition 
ELISA. Possible role of the RNS modified DNA in Cancer and SLE has been probed by 
studying the binding of the circulating autoantibodies with the modified and native DNA. 
Anti-RNS-DNA IgG has been used to detect damage in the DNA isolated from different 
cancer patients. The results have been compared with the binding of induced IgG to the 
DNA isolated from healthy subjects. 
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MATERIALS 
Chemicals 
Human placental DNA, bovine serum albumin, methylated bovine serum 
albumin, anti-human and anti-rabbit IgG alkaline phosphatase conjugates, p-nitrophenyl 
phosphate, Freunds complete and incomplete adjuvants, ethidium bromide, Coomassie 
Brilliant Blue G250 and R250, sodium dodecyl sulphate, Tween-20, synthetic 
polynucleotides, agarose, mannitol, PTIO, DTPA and superoxide dismutase were 
purchased from Sigma Chemical Company, U.S.A. Protein A-Sepharose CL-4B, 
nuclease SI, were from GENEI India, Ficoll-400 was obtained from Pharmacia Fine 
Chemicals Sweden, SNP (sodium nitroprusside), pyrogallol, EDTA, chloroform, isoamyl 
alcohol, uric acid, ascorbic acid were from Qualigens, India. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm diameter) 
were purchased from Nunc, Denmark. Qiagen's QIA amp DNA blood Midi Kit was 
supplied by Genetix, India, Folin-Ciocalteau reagent was from Centre for Biochemical 
Technology, New Delhi. Acrylamide, ammonium persulphate, bisacrylamide, N,N, N , 
N - tetramethylethylenediamide (TEMED) were obtained from Bio-Rad Laboratories, 
U.S.A. All other chemicals were of highest analytical grade available. 
Equipments 
Shimadzu UV-240 Spectrophotometer equipped with thermo-programmer and 
controller unit, ELISA microplate reader (Labsystems, Finland), ELISA microplate 
washer (Denley, England), ELICO pH meter model LI-IOT, ultraviolet lamp (Vilber 
Lourmat, France). Agarose gel electrophoresis apparatus (Pharmacia, Sweden), Avanti-
30 table top high speed refrigerated centrifuge (Beckman, U.S.A.), polyacrylamide gel 
electrophoresis assembly (Bio-Rad, U.S.A.) Spectrofluorophotometer (Hitachi, Japan) 
were the major equipments used in this study. 
Collection of Blood and Serum Samples 
Serum and blood samples were collected from normal human subjects and cancer 
patients with histopathological diagnosis. SLE sera were obtained from patients showing 
high titre anti-DNA antibodies and fijlfilling the American College of Rheumatology 
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criteria for the diagnosis of the disease. Sera were decomplemented by heating at 56°C 
for 30 minutes and stored in ahquots at -80°C with 0.1% sodium azide. 
METHODS 
Purification of DNA 
Commercially obtained highly polymerized human placental DNA was purified 
free of proteins, RNA and single stranded regions, (Ali et al., 1985). The DNA (2 mg/ml) 
was dissolved in O.IX SSC (15 mM sodium citrate and 150 mM sodium chloride) pH 7.3 
and mixed with an equal volume of chloroform-isoamyl alcohol (24:1) mixture. The 
sample was extracted in a stoppered measuring cylinder for 1 hour and aqueous layer 
containing DNA was separated from the organic layer and re-extracted by mixing with 
fresh mixture of chloroform isoamyl alcohol. The DNA in aqueous layer was 
precipitated with two volumes of cold absolute ethanol and collected on a glass rod. 
After air drying, the DNA was dissolved in acetate buffer (30 mM each of sodium 
acetate and zinc chloride) at pH 5.0 and treated with nuclease SI (150 units/mg DNA) at 
37°C for 30 minutes to remove single stranded regions. The reaction was stopped by 
adding one-tenth volume of 200 mM EDTA pH 8.0. The nuclease SI treated DNA was 
extracted twice with a mixture of chloroform-isoamyl alcohol and finally precipitated 
with two volumes of cold ethanol. The precipitated DNA was dissolved in phosphate 
buffered saline (PBS) (lOmM sodium phosphate containing 150 mM sodium chloride) 
pH 7.4. 
Determination of DNA Concentration 
The concentration of DNA was determined by the method of Burton (1956) 
(a) Crystallization of diphenylamine 
Diphenylamine (2 gm) was dissolved in 200 ml boiling hexane. Approximately 
0.5 gm of activated animal charcoal was added and filtered through Whatman 
filter paper. The filtrate was kept overnight at 4°C. Diphenylamine crystals so 
obtained, were again filtered to remove hexane and finally dried at room 
temperature. 
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(b) Preparation of diphenylamine reagent 
Recrystallized diphenylamine (750 mg) was dissolved in 50 ml glacial acetic 
acid containing 0.75 ml concentrated sulphuric acid. 
(c) Procedure 
One ml of IN perchloric acid was added to 1.0 ml of DNA sample and incubated 
in a thermostat water bath at 70°C for 15 minutes. One hundred microlitre of 5.43 mM 
acetaldehyde was added followed by 2.0 ml of freshly prepared diphenylamine reagent. 
The contents were mixed and incubated at room temperature for 16-20 hours and 
absorbance was recorded at 600 nm. The DNA concentration in unknown samples was 
determined using purified human DNA as standard. 
Determination of Protein Concentration 
Protein was estimated by the methods of Lowry et al, (1951) and Bradford (1976) 
Protein Estimation by Folin's-Plienol Reagent 
Protein estimation by this method utilizes alkali (to keep the pH high), Cu^^  ions 
(to chelate proteins and tartarate (to keep the Cu^^  ions in solution at high pH). 
(a) Folin-Ciocalteau reagent 
The reagent was obtained commercially and diluted 1:4 with distilled water 
before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows. 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) 
and (ii) in a ratio of 50:1 
(c) Procedure 
To 1.0 ml of protein sample was added 5.0 ml of alkaline copper reagent. The 
samples were allowed to stand at room temperature for 10 minutes. Working Folin-
Ciocalteau reagent (1.0 ml) was added to the tubes, mixed and incubated for 30 minutes 
at room temperature. The absorbance was recorded at 660 and the concentration of 
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protein in unknown sample was determined from a standard plot constructed by using 
varying concentrations of bovine serum albumin. 
Protein Estimation by Dye Binding Method 
This assay is based on colour change that occurs when Coomassie Brilliant Blue 
G-250 in acidic medium binds strongly to protein hydrophobically at positively charged 
groups, protonation is suppressed and a blue colour is observed (A,max= 595 nm). 
(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% 
ethanol. To this solution was added 100 ml of 85% (v/v) orthophosphoric acid. The 
resulting solution was diluted to a final volume of 1 litre. 
(b) Protein assay 
To 1.0 ml solution containing 10-100 )ig protein, was added 5 ml of dye solution 
and contents were mixed by vortexing. The absorbance was taken at 595 nm after 
5 minutes against a reagent blank. 
Modification of Human Placental DNA by the Synergistic Action of SNP and 
Pyrogallol 
Aqueous solution of native human placental DNA in PBS pH 7.4 was incubated 
with SNP and progallol in presence of a chelator, DTPA for 3 hr at 37°C. Excess of SNP 
and pyrogallol were removed by extensive dialysis against PBS pH 7.4. Native human 
DNA samples treated with SNP or pyrogallol alone served as controls. 
Spectroscopic Analysis 
(a) Ultraviolet spectroscopy 
The ultraviolet (UV) spectra of modified and unmodified human DNA were 
recorded in the wavelength range of 200 nm to 400 nm on a Shimadzu UV-240 
spectrophotometer. 
(b) Fluorescence spectroscopy 
Fluorescence emission spectroscopy of native and modified human DNA was 
performed using ethidium bromide on a Hitachi fluorimeter. 
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(c) Absorption-temperature-scan 
Thermal denaturation analysis of nucleic acids was performed in order to ascertain 
the degree of modification incurred on the nucleic acid by determining mid - point 
melting temperature (Tm) Native and modified-human DNA as well as 
corresponding controls were subjected to heat denaturation on a Shimadzu UV-240 
spectrophotometer coupled with a temperature programmer and controller assembly 
(Hasan and AH, 1990). All samples were melted from 30°C to 95°C at a rate of 
1.5°C per minute after 10 minutes equilibration at 30°C. The changes in absorbance 
at 260 nm were recorded with increasing temperature. Percent denaturation was 
calculated as follows: 
A T - A30 
Percent denaturation = x 100 
Amax - A30 
where, 
AT = Absorbance at temperature T°C 
Amax = Final maximum absorbance on completion of denaturation 
A30 = Initial absorbance at 30°C 
Detection of Strand Breaks 
The damage to DNA was ascertained by alkaline agarose electrophoresis and 
nuclease S1 digestion. 
Alkaline Agarose Gel Electrophoresis 
Native and modified human DNA (3 |ag each) were treated with 0.062 N 
NaOH/f^g of DNA for 20 min at 37°C and electrophoresed under alkaline conditions. 
The untreated native and modified human DNA served as controls. 
(a) Gel preparation 
Agarose (1%) in distilled water containing 2 mM EDTA was dissolved by 
heating. The solution was cooled to 60°C and then poured into gel tray by adding 
30 mM NaOH and allowed to solidify at room temperature. 
(b) Sample preparation and loading 
Native and modified DNA samples were treated with NaOH then mixed with one 
tenth volume of sample dye (0.125% Bromophenol Blue, 30% Ficoll 400, 500 
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mM EDTA in lOX electrophoretic buffer containing 300 mM NaOH and 6 mM 
EDTA). The samples were loaded in wells and electrophoresed for 2 hr at 30 V in 
electrophoretic buffer containing 5 mM NaOH and ImM EDTA in distilled water 
(pH 8.0). The gel was then equilibrated with 5-6 changes of Tris- HCl buffer (20 
mM Tris- HCl pH 7.6) followed by staining with ethidium bromide (0.5 |J.g/ml) 
and visualization under UV light. 
Nuclease SI Digestibility 
Native and modified human DNA were characterized by nuclease SI digestibility 
(Matsuo and Ross, 1987). One microgram each of native and modified DNA in acetate 
buffer (30 mM each of sodium acetate and zinc chloride, pH 5.0) were treated with 
nuclease SI (10 units per [ig DNA) for 30 minutes at 37°C. The nuclease SI digested 
and control samples were subjected to agarose gel electrophoresis. 
(a) Gel preparation 
Agrose (1%) in TAE buffer (40mM Tris-acetate, pH 8.0 containing 2mM EDTA) 
was dissolved by heating. The solution was cooled to about 50°C and then poured 
into the gel tray and allowed to solidify at room temperature. 
(b) Sample preparation and loading 
Native and modified DNA samples treated with nuclease SI were mixed with one-
tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400, 500 mM 
EDTA in lOX electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 1 Vi hour at 36 mA. The gels were stained with ethidium bromide 
(0.5^g/ml) and viewed by illumination under UV light and photographed. 
Quenching Studies 
Quenching studies were done to ascertain the production and type of free radical 
causing damage, during modification of human placental DNA. l|ig of human DNA was 
incubated with SNP and pyrogallol in presence of different quenchers for 3 hr at 37°C. 
Native human DNA and modified human DNA without quenchers served as control. 
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(a) Gel preparation 
Agrose 1% in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM EDTA) 
was dissolved by heating. The solution was cooled to about 50°C and then poured 
into gel tray and allowed to solidify at room temperature. 
(b) Sample preparation and loading 
Samples were mixed with one-tenth volume of sample buffer (0.125% 
Bromophenol Blue, 30% Ficoll 400, 500 mM EDTA in lOX electrophoretic 
buffer). The samples were loaded in the wells and electrophoresed for 1V2 hr at 
37 mA and visualized under UV light and photographed. 
Immunization Scliedule 
Native and modified-human DNA (50 j^ g each) were complexed with an equal 
amount (w/w) of methylated BSA and emulsified with an equal volume of complete 
Freund's adjuvant and injected intramuscularly in female rabbits. Subsequent injections 
were given in incomplete Freund's adjuvant. Each animal received a total of 500 )^ g of 
antigen in the course of 10 injections. Blood was collected from ear, serum was 
separated and decomplemented by heating at 56°C for 30 minutes. Pre-immune sera was 
collected prior to immunization. The sera were stored in small aliquotes at -80°C with 
few drops of O.P/o sodium azide as preservative. 
Isolation of IgG 
Immunoglobulin G was isolated from serum by affinity chromatography on 
Protein A-Sepharose CL-4B column. Serum (0.5 ml), diluted with equal volume of PBS, 
pH 7.4 was applied to the column equilibrated with the same buffer. The wash through 
was recycled 2-3 times. Unbound IgG was removed by extensive washing with PBS, pH 
7.4. The bound IgG was eluted with 0.58%) acetic acid in 0.85%) sodium chloride 
(Golding, 1976). Three ml fractions were collected in a measuring cylinder already 
containing 1ml of IM Tris-HCl, pH 8.5 and absorbance was recorded at 251 nm and 278 
nm. IgG concentration was determined considering 1.4 OD280 = TO mg mammalian 
IgG/ml. Isolated IgG was then dialyzed against PBS, pH 7.4 and stored at -80°C with 
0.1% sodium azide. 
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Polyacrylamide Gel Electrophoresis 
Polyacrylamide slab gel electrophoresis was performed under non-denaturing 
conditions as described by Laemmli (1970). The following stock solutions were 
prepared. 
(a) Acrylamide-Bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
bisacrylamide in distilled water to a final volume of 100 ml. Solution was filtered 
and store at 4°C in an amber coloured bottle. 
(b) Resolving Gel Buffer 
A stock solution was prepared by dissolving 36.3 gm of Tris base in 48.0 ml of 
IN HCl. The contents were mixed, pH adjusted to 8.8 and the final volume 
brought to 100 ml with distilled water. 
(c) Stacking Gel Buffer 
6.05 gm Tris was dissolved in 40ml distilled water, pH titrated to pH 6.8 with I.O 
N HCl and the final volume adjusted to 100 ml with distilled water. 
(d) Electrode Buffer 
The electrode buffer used was TAE (40 mM Tris, 1.14 ml glacial acetic acid and 
ImM EDTA), pH 7.9 
(e) Procedure 
The PAGE assembly was set up and glass plates separated by 1.5 mm thick 
spacer were sealed with 1% agarose fi-om sides and bottom. The non-denaturing 
gel was prepared and poured between the glass plates and allowed to polymerize 
at room temperature. Nucleic acid samples were mixed with one-tenth volume of 
stopmix (30% Ficoll, 0.025% Xylene Cyanole FF and 500 mM EDTA in 10 
times concentrated TAE buffer) and applied onto the gel. The gel was 
electrophoresed for 8-10 hr at room temperature at 80 Volts, stained with 
ethidium bromide (0.5 |Jg/ml) and visualized under UV light. 
Recipe For 7,5% Non-Denaturing PAGE 
Acrylamide-bisacrylamide 
Resolving gel buffer 
1.5% ammonium per sulphate 
Distilled water 
TEMED 
10.0 ml 
5.0 ml 
1.5 ml 
23.5 ml 
20.0 ^ 1 
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PAGE for Proteins 
A 7.5% resolving gel was layered with 2.5% stacking gel according to the 
composition given in table 
SOLUTIONS 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10%SDS 
1.5% ammonium persulphate 
TEMED 
STACKING GEL 
2.5 ml 
5.0 ml 
-
11.3 ml 
0.2 ml 
1.0 ml 
15^1 
RESOLVING GEL 
7.5 ml 
-
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15^1 
Protein samples were mixed with one fourth volume of sample buffer (10% 
glycerol and 0.002% Bromophenol Blue in 10 times concentrated 0.5 M Tris-HCl pH 
6.8) and applied onto the gel and electrophoresed at 70 volts for 6-8 hr using Tris-glycine 
buffer (25 mM Tris, 192 mM glycine containing 1% SDS), pH 8.3. The gels were stained 
overnight with 0.1 %> Coomassie Brilliant Blue R250 (in 25%o isopropanol and 10% 
glacial acetic acid). Destaining was carried out with a mixture of 30%) methanol and 10%) 
glacial acetic acid. 
Detection and Quantitation of Antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay and gel 
retardation. 
(a) Enzyme linked Immunosorbent Assay (ELISA) 
The antibodies were detected and quantitated by ELISA on flat bottom 96 well 
microtitre plates according to the method of 
Buffers and Reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl pH 7.5 containing 500 i^ l Tween-
20/litre 
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Carbonate-bicarbonate buffer 
15mM sodium carbonate, 35 mM sodium bicarbonate 
containing 2mM magnesium chloride, at pH 9.6 
Substrate 
500 )j,g of p-nitrophenylphosphate /ml of carbonate bicarbonate buffer, pH 9.6. 
Procedure 
The test wells of microtitre plates were coated with 100 \i\ of antigen (2.5 |J.g/ml 
in TBS) for 2 hr at 37°C and overnight at 4°C. The antigen coated wells were washed 
three times with TBS-T to remove unbound antigen. Unoccupied sites in the wells were 
blocked with 150 |LI1 of 1.5% BSA in TBS for 5 hours at room temperature. The plates 
were washed once with TBS-T and antibody (100 j^ l of 1:100 diluted serum in 
TBS/well) to be tested, were absorbed for 2 hr at room temperature and over night at 
4°C. The unbound antibody was washed off 4 times using TBS-T. An appropriate anti-
immunoglobulin alkaline phosphatase conjugate (100 |j.l of 1:2000 dilution) was added 
to each well. After incubation at 37°C for 2hr. Plates were washed four times with TBS-
T and three times with distilled water and developed using p-nitrophenylphosphate 
substrate. The absorbance was recorded at 410 nm on an automatic microplate reader 
after proper colour development. Each sample was run in duplicate. The control wells, 
treated similarly, were devoid of antigens. Results were expressed as a mean of 
•^test " • 'Control-
(b) Competition ELISA 
The antigenic specificity of the antibodies was determined by competition ELISA 
(Hasan et al., 1991). Varying amounts (0-20 )J.g/ml) of inhibitors were mixed with 100 |LI1 
of 1:100 diluted antiserum. The mixture was incubated at room temperature for 2 hr and 
overnight at 4°C. The immune complex thus formed was coated in the wells and direct 
binding ELISA was performed. Percent inhibition was calculated using the formula. 
A:. 
Percent inhibition 
where, 
1 __ ' inhibited 
A 
uninhibited 
xlOO 
A inhibited = Absorbancc at 20 )Jg/ml inhibitor concentration 
A uninhibited = Absorbancc at zero inhibitor concentration 
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(c) Gel Retardation Assay 
For the visual detection of antigen-antibody interaction and immune complex 
formation gel retardation assay was performed (Sanford et al, 1988). A constant amount 
of antigen (native and modified human DNA, one |a.g each) was incubated with varying 
amounts of IgG in PBS, pH 7.4 for 2 hr at 37°C and overnight at 4°C. One tenth volume 
of stopmix dye (0.25% Xylene Xyanole and 15% FicoU 400) was added to the samples 
and electrophoresed on 1% agarose for 2 hr at 30 mA in 40 mM Tris-acetate buffer, pH 
7.9. The gels were stained with ethidium bromide (0.5 i^g/ml), visualized under UV light 
and photographed. 
Isolation of DNA from Human Blood 
Blood samples were collected in EDTA vials from cancer patients and healthy 
individuals. DNA was harvested from fresh blood in a stepwise procedure using QIA 
amp DNA isolation kit. To around 2 ml of blood, 200X protease stock solution and 2.4 
ml Buffer AL was added. Contents were thoroughly mixed, incubated at 70°C for 10 min 
followed by the addition of 4 ml of ethanol (95%-100%) and by vortexing. Solution was 
transferred into the column provided with centrifugation tube and centrifuged at 3000 
rpm for 3 min. Filtrate was discarded and AWi buffer was added and centrifuged at 5000 
rpm for one minute, followed by addition of AW2 and again performing centrifugation at 
5000 rpm. for 15 minutes. 
The column was placed back in a fresh 15ml centrifugation tube, and 300 |j,l of 
buffer AE was added into the column and incubated at room temperature for 5 minutes 
and then centrifuged at 500 rpm, for 5 minutes. DNA is eluted in buffer AE. 
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Modification of Human Placental DNA by RNS 
Commercially available human placental DNA, purified free of protein, RNA 
and single stranded regions was modified by the synergistic action of a nitric oxide donor 
(SNP) and a polyhydroxy aromatic compound pyrogallol in presence of a chelating agent 
DTPA. The reaction was carried out for 3 hr at 37°C such that 0.075 mM bp DNA was 
damaged by SNP:Pyrogallol:DTPA each having a concentration of 0.5 mM. After 
completion of reaction the mixture was extensively dialyzed against PBS, pH 7.4 to 
remove excess of salts. 
Characterization of Modified Human DNA 
(a) Ultraviolet Absorption Spectral Studies 
The ultraviolet (UV) absorption spectra of RNS modified DNA showed an 
increase in absorbance over the entire UV range with a marked hyperchromicity of 
29.4% at 260 nm and a shift of 6 nm towards longer wavelength. The corresponding 
controls i.e. DNA-SNP and DNA-pyrogallol, respectively exhibited 0.0% and 14.2% 
hyperchromic effect relative to native DNA (Fig. 6). Peak shift of 3 nm towards greater 
wavelength was also observed in case of control samples. It was further observed that if 
either the concentration of SNP or pyrogallol is varied such that their 1:1 ratio is 
disturbed, no damage is caused to the DNA even at higher molarities. The absorption 
characteristics of native and modified DNA are given in Table 4. 
(b) Fluorescence Emission Spectra 
The fluorescence emission spectra of both native and modified human DNA was 
recorded on a spectrofluorophotometer. ft was observed that relative to native DNA, 
modified DNA fluoresced to a lesser extent. The maximum fluorescent intensity of 
nafive DNA was 22.15 whereas for the modified one it was 7.8 at an excitafion of 260 
nm. A stokes shift of 5 nm was also observed upon RNS- modification. Further it was 
found that the quantum efficiency was decreased three times relative to native DNA 
( Fig 7; Table 5). 
Thermal Denaturation of Native and Modified Human DNA 
The thermal transitions induced in DNA and its modified analog were observed 
by heating the samples at a rate of 1.5°C/min. Melting profile of modified and control 
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Fig. 6. Ultraviolet absorption spectra of native DNA ( ), SNP treated DNA 
( ), Pyrogallol treated DNA ( •), SNP-Pyrogallol treated 
DNA( ) 
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TABLE 4 
Ultraviolet Absorption Characteristics of Native and Modified 
Human DNA Under Identical Experimental Conditions 
PARAMETERS 
Absorbance ratio 
(A260/A280) 
Percent increase in 
hyperchromicity 
Maximum absorbance 
Minimum absorbance 
(A-maxJ 
NATIVE 
DNA 
1.8 
-
260 run 
230 nm 
SNP-DNA 
1.6 
0.0 
260 nm 
233 run 
PYROGALLOL-
DNA 
1.47 
14.2 
260 nm 
233 nm 
SNP-
PYROGALLOL -
DNA 
1.3 
29.4 
260 run 
236 run 
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Fig.7. Fluorescence emission spectra of native ( 2 ) and RNS-DNA ( 1 ). 
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TABLE 5 
Fluorescence Characteristics of Native and Modified Human DNA 
Under Identical Conditions 
PARAMETERS 
I560 (Intensity of fluorescence at 560 nm) 
If (Maximum fluorescent intensity) 
Wavelength at which If is achieved 
Stokes shift 
Ratio of quantum efficiency 
Excitation wavelength 
NATIVE 
HUMAN DNA 
14.5 
22.15 
610nm 
-
3 
260 nm 
MODIFIED 
HUMAN DNA 
4 
7.8 
615 nm 
5 nm 
1 
260 nm 
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samples were analyzed spectroscopically between 30°C to 95°C at 260 nm. Increase in 
absorbance at 260 nm was taken as a measure of helix denaturation. The process was 
characterized by determining the percent DNA in denatured state as a function of 
increase in the temperature by computing the melting temperature (Tm) values where 
half of the helix is melted i.e. 50% helix opening of native human DNA, SNP-DNA, 
Pyrogallol-DNA, RNS-DNA. The observed Tm values were 87.5°C, 87.0°C, 85.0°C, 
81.5°C, respectively (Table 6). A significant decrease of 6.8% in Tm of RNS- DNA was 
observed as compared to the native DNA control. While for SNP-DNA and pyrogallol-
DNA the decrease in Tm, relative to native conformer, was 0.57% and 2.85%> 
respectively (Fig.8). Lowering of Tm values indicates structural alteration and single 
strand generation following modification. 
Electrophoretic Pattern 
The electrophoretic pattern of RNS modified human DNA along with native, 
SNP and pyrogallol ti'eated human DNA was analysed on 1% agarose gel wherein it was 
observed that native, SNP, pyrogallol DNA migrated as uniform linear stretch whereas 
native DNA upon R>[S modification exhibited a short stretch much away from the point 
of application of sam]ple with a slight decrease in fluorescent intensity (Fig. 9) indicating 
structural alterations in DNA upon modification (Table 7). 
Nuclease SI Digestibility 
Native and modified human DNA, alongwith proper controls were subjected to 
nuclease SI digestion at a concentration of 10 units/^g DNA for 30 min and 
electrophoresed on 1% agarose gel. It was clearly observed that the single strand specific 
enzyme was not abl(2 to digest native and SNP-DNA whereas pyrogallol-DNA was 
digested to some extent. However, the digestion was much pronounced in the case of 
RNS-DNA. Further, it was observed that native DNA, SNP-DNA and pyrogallol-DNA 
showed almost identical electrophoretic migration pattern whereas RNS-DNA migrated 
faster than the controls. Almost identical fluorescence intensity was observed for native-
DNA and SNP-DNA treated with SI nuclease whereas pyrogallol-DNA and RNS-DNA 
exhibited decreased intensity (Fig. 10). The later specie showing least intense band. 
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TABLE 6 
Physicochemical Characteristics of Native and Modified Human DNA Under 
Identical Experimental Conditions 
PARAMETERS 
Native human DNA 
SNP-human DNA 
Pyrogallol-human DNA 
SNP-pyrogallol-human DNA 
ONSET OF 
DUPLEX 
MELTING (°C) 
82 
77 
70 
38 
MELTING 
TEMPERATURE 
Tm (°C) 
87.5 
87 
85 
81.5 
PERCENT 
DECREASE IN 
Tm (°C) 
-
0.57 
2.85 
6.8 
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Fig. 8(a) Thermal denaturation profile of native (-0-) and modified (-•-) DNA. 
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Fig. 9. Agarose gel electrophoresis of native and modified DNA. Lanes (1) 
native DNA, (2) SNP-DNA, (3) pyrogallol-DNA, (4) RNS-DNA. 
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TABLE 7 
Electrophoretic Parameters of Native and Modified forms of DNA 
Native 
human-DNA 
SNP-human-
DNA 
Pyrogallol-
human-DNA 
SNP-
Pyrogallol 
human-DNA 
MOBILITY 
FROM WELL 
+ 
+ 
+ 
INTENSITY 
+++ 
+++ 
++ 
+ 
SI 
SENSITIVITY 
-
-
+ 
+++ 
ALKALINE 
SUSCEPTIBILITY 
+ 
+++ 
++• Maximum value for a particular parameter. 
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Fig. 10. Nuclease SI sensitivity of native and modified DNA. Lanes (1) native 
DNA, (2) nuclease SI treated native DNA, (3) RNS-DNA, (4) nuclease 
SI treated RNS-DNA, (5) SNP-DNA, (6) nuclease SI treated SNP-DNA, 
(7) pyrogallol-DNA, (8) nuclease SI treated pyrogallol-DNA. 
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Alkaline Agarose Gel Electrophoresis 
The native and modified human DNA (l|a.g each) were treated with NaOH 
(0.062 N) for 20 min at 37°C. Samples were electrophoresed under alkahne conditions at 
30 Volts for 2 hr. A very faint band was observed in the case of modified DNA, 
undigested native and modified forms of DNA served as controls (Fig. 11). The data 
shows that modified DNA is highly susceptible to digestion under alkahne conditions as 
compared to native DNA. The result clearly demonstrates that the B-helix is sufficiently 
destabilized as a result of RNS induced modification (Table 7). 
Quenching Studies 
Human DNA was modified in the presence of different quenchers of various 
radicals in order to shut off the effect of one specie and let the other modify the hehx. All 
the samples were analyzed on 1% agarose gel (Fig. 12). When modification was carried 
out in presence of PTIO, a quencher for nitric oxide, no modification was observed. 
Ascorbic acid, superoxide dismutase and uric acid, known quenchers of super oxide 
radical prevented modification to a greater extent under defined reaction conditions. No 
quenching effect was observed with mannitol, a known quencher of OH radical. The 
results indicate that maximum modification is caused by the synergistic action of nitric 
oxide and superoxide radical. 
Antigenicity of Modified Human DNA 
The antigenicity of modified human DNA was determined by inducing antibodies 
in rabbits. Antigenic specificity of the induced antibodies was assayed by direct binding 
and competition ELISA. Binding of immune IgG to the immunogen and native human 
DNA was further probed by band shift assay. 
Antibodies against RNS-Human DNA 
The antibodies induced in response to RNS-human DNA were found to be non-
precipitating as assessed by double immunodiffusion. The antiserum showed a high titer 
(>1.T2800) when tested by direct binding ELISA (Fig.13). Preimmune sera served as 
negative control, and did not show any appreciable binding. Immunization with native 
DNA did not elicit appreciable antibody response. 
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1 3 h 
Fig. 11. Alkaline agarose gel electrophoresis of native and modified human DNA. 
Lanes (1) native human DNA, (2) native human DNA under alkaline 
conditions, (3) RNS-DNA, (4) RNS-DNA under alkaline conditions. 
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Fig. 12. Agarose gel electrophoresis of native DNA and RNS-DNA in presence of 
different quenchers. Lane (1) native DNA, (2) RNS-DNA, (3) 
modification in presence of PTIO, (4) modification in presence of 
ascorbic acid, (5) modification in presence of mannitol, (6) modification 
in presence of SOD, (7) modification in presence of uric acid. 
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Fig. 13. Direct binding ELISA of anti-RNS-DNA antibodies (-•-) and 
pre-immune sera (-•-)• The microtitre plates were coated with RNS-
DNA (2.5 fxg/ml). 
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The specificity of anti-RNS-DNA antibodies was evaluated by competition 
ELISA. A maximum of 40% inhibition in the antibody activity was obtained when native 
DNA was used as an inhibitor while 67% inhibition in antibody activity was obtained at 
an immunogen concentration of 20 |j,g/ml. Concentration of immunogen, as competitor, 
required for 50% inhibition was 17 [ig/ml (Fig. 14-15). 
Purification and Binding Characteristics of Immune IgG 
Immunoglobulin G was isolated from preimmune and immune serum of rabbits 
immunized with RNS modified DNA, by affinity chromatography on a Protein A-
Sepharose CL-4B column (Fig. 16). Purity of IgG was evaluated by SDS-polyacrylamide 
gel electrophoreses in the absence of a reducing agent. The purified IgG migrated as a 
single band upon electrophoresis. Direct binding ELISA of the purified IgG showed high 
reactivity with the immunogen. Pre-immune IgG, as negative control, showed negligible 
binding to the immunogen (Fig. 17). 
Antigenic Specificity of Anti-RNS-DNA IgG 
The anti RNS-DNA IgG exhibited a broad spectrum of cross reactivity as 
observed by its binding to various nucleic acids, synthetic polynucleotides and nuclear 
proteins. A maximum of 85%o inhibition was obtained with immunogen as an inhibitor 
(Fig.18). For 50% inhibition in antibody activity, 10 |ig/ml of RNS-DNA was required. 
Native and RNS-modified calf thymus DNA showed a maximum inhibition of 
30 % and 70%) and to achieve 50%) inhibition 15 ng/ml of RNS-modified calf thymus 
DNA was required. O2" modified 400 bp DNA and its native analog showed maximum 
inhibition of 31%o and 20% respectively (Fig. 19). Chromatin, ROS-chromatin, 
chondroitin sulphate and cardiolipin inhibited antibody activity by 25%), 56%o, 31%, 42% 
respectively at 20 \ig/m\ of inhibitor concentration (Fig. 20). 
Synthetic nucleic acid polymers such as poly(dG-dC), poly(dA), poly(dT), 
poly(G) were capable of inhibiting antibody activity by 20%, 14%, 27%, and 29%, 
respectively at a maximum inhibitor concentration of 20 |ig/ml (Fig. 21). 
Table 8 summarizes the results of inhibition of anti-RNS human DNA IgG 
binding to RNS-human DNA by various competitors as evaluated by inhibition ELISA. 
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Fig. 14. Inhibition ELISA of anti-RNS-DNA immune (-•-) and pre-immune 
(-•-) sera with native human DNA. The microtitre plates were coated 
with RNS-DNA (2.5 ^ g/ml). 
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Fig. 15. Inhibition ELISA of anti-RNS-DNA immune (-•-) and pre-immune 
(_#_) sera with RNS-DNA. The microtitre plates were coated with 
RNS-DNA (2.5 \ig/m\). 
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FRACTION NUMBER 
Fig. 16. Elution profile of anti-RNS-DNA IgG on a Protein A-Sepharose CL-4B 
column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 17. Direct binding ELISA of anti-RNS-DNA immune (-•-) and pre-immune 
IgG (-•-) . The microtitre plates were coated with RNS-DNA(2.5 )iig/ml). 
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Fig. 18. Inhibition ELISA of anti-RNS-DNA immune (-•-) and pre-immune 
(-•-) IgG with RNS-DNA. The microtitre plates were coated with 
RNS-DNA (2.5 ^ g/ml). 
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Fig. 19. Inhibition of immune IgG binding to modified DNA. The competitors 
were O2" 400 bp calf thymus DNA (-•-) , 400 bp calf thymus DNA 
(-•-) , native calf thymus DNA (-A-), RNS-calf thymus DNA (-T-). 
The microtitre plate was coated with RNS-DNA (2.5 ^ g/ml). 
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Fig. 20. Inhibition of immune IgG binding to modified DNA. The competitors 
were chromatin (-•-), ROS-chromatin (-•-) , cardiohpin (-A-), and 
chondroitin sulphate ( - • - ) . The microtitre plate was coated with 
RNS-DNA (2.5 ng/ml). 
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Fig. 21. Inhibition of immune IgG binding to modified DNA. The competitors 
were poly d[C] (-•-), poly d[T] (-•-) , poly d[A] (-A-), poly [dG-dC] 
( -T- ) . The microtitre plates were coated with RNS-DNA. 
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TABLE 8 
Antigenic Specificity of Anti-RNS Human DNA IgG 
INHIBITORS 
RNS-human DNA 
Native-human DNA 
O2" 400 bp calf thymus DNA 
Native 400 bp calf thymus DNA 
Native chromatin 
ROS-chromatin 
Chondroitin sulphate 
Cardiolipin 
Native calf thymus DNA 
RNS-calf thymus DNA 
Poly(dA) 
Poly(dC) 
PoIy(dT) 
Poly(dG-dC) 
MAXIMUM 
PERCENT 
iNHromoN 
AT 20 ^ g/ml 
85 
45 
31 
20 
22 
31 
31 
42 
30 
60 
14 
29 
27 
20 
INHIBITOR 
CONCENTRATION 
FOR 50% 
INHIBITION 
10 
-
-
-
-
-
-
-
-
14 
-
-
-
-
PERCENT 
RELATIVE 
AFFINITY 
100 
71 
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The relative binding affinity of immune IgG with various inhibitors has also been 
calculated. 
Band Shift Assay with Immune IgG 
Visual detection of binding of anti RNS-DNA IgG to native and RNS- DNA was 
observed by band shift assay. The assay involves antigen-antibody interaction such that 
a constant amount (l^g) of native and RNS-DNA are incubated with varying amounts of 
immune IgG (10 to 60 i^g) for 2 hr at 37°C and overnight at 4°C. The resulting immune 
complexes were electrophoresed on 1% agarose for VA hr at 30 mA. It is clearly seen 
that increasing the concentration of IgG leads to the formation of high molecular weight 
immune complexes which are retained in the well thereby retarding the mobility and 
intensity of antigen (Fig. 22). Retarded mobility was more pronounced with RNS-DNA 
as compared to native DNA. 
Recognition of RNS-DNA by SLE Autoantibodies 
In order to determine the recognition of RNS-modified DNA by circulating anti-
DNA antibodies, binding of 24 SLE sera (1:100) to native and RNS-DNA was assayed 
by ELISA (Fig. 23). Of the 24 sera tested, all but 3, showed greater reactivity to RNS-
DNA as compared with native human DNA. Thus, modification presents epitopes which 
are recognized more significantly by SLE autoantibodies. 
Antigen Binding Specificity of SLE Autoantibodies 
The specificity of 12 best binding sera for native and RNS-DNA was evaluated 
by competitive binding assay. Antibody was incubated with increasing concentrations 
(0-20 |J.g/ml) of inhibitors (native and RNS-DNA) and then assayed for residual binding 
to double stranded human DNA. Out of 12 sera tested only 2 achieved 50% inhibition in 
case of native DNA whereas 9 achieved more than 50% inhibition when RNS-DNA was 
used as an inhibitor. Native human-DNA produced an inhibition of 50% while with 
RNS-DNA 70% inhibition in the antibody activity was observed. Inhibitor concentration 
in both the cases being 20 )ig/ml. Results are summarized in tables 9-10 and in figures 
24-29. For all of the 12 sera tested the t value was found to be 4.50 at df =22 and p value 
73 
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Fig.22. Band shift assay of anti-RNS-DNA IgG binding to (a) native DNA and 
(b) RNS-DNA. Native DNA and RNS-DNA (l|ig each) were incubated 
with IgG for 2 hr at 37 °C and overnight at 4°C. Electrophoresis was 
carried out on 1% agarose gel for 2 hr at 30 mA. Lane 1 contain native or 
RNS-DNA while lanes 2, 3, 4 and 5 contain native or RNS-DNA with 10, 
20, 40, 60 |ug of immune IgG. 
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Fig. 23. Binding of various SLE sera to native (-•-) and modified DNA 
(-ri-). The histogram show absorbance values for binding of NHS and 
sera from SLE patients. The microtitre plate was coated with RNS-DNA 
(2.5 pg/ml). Serum no. 23 represents NHS which served as negative 
control. 
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Fig. 24. Detection of antibodies against native DNA in the sera of patients with 
SLE. The microtitre plates were coated with RNS-DNA (2.5 i^g/ml). 
Cuirves (-•-), (-•-), (-A-), ( - • - ) represent sera from different SLE 
patients. 
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Fig. 25. Detection of antibodies against native DNA in the sera of patients with 
SLE. The microtitre plates were coated with RNS-DNA (2.5ng/ml). 
Cuirves (-•-), (-•-), (-A-), ( - • - ) represent sera from different SLE 
patients. 
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Fig. 26. Detection of antibodies against native DNA in the sera of patients with 
SLE. The microtitre plates were coated with RNS-DNA (2.5 ng/ml). 
Cui:A'es (-•-), (-•-) , (-^-)) ("•") represent sera from different 
patients with SLE. 
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Fig. 27. Detection of antibodies against RNS-DNA in the sera of patients with 
SLE. The microtitre plates were coated with RNS-DNA (2.5 ng/ml). 
Cuirves (-•-), (-•-) , (-A-), ( - • - ) represent sera from different SLE 
patien1;s. 
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Fig. 28. Detection of antibodies against RNS-DNA in the sera of patients with 
SLE. The microtitre plates were coated with RNS-DNA (2.5 |ig/ml). 
Curves (-•-), (-•-), (-A-), ( - • - ) represent sera from different SLE 
patients. 
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Fig. 29. Detection of antibodies against RNS-DNA in the sera of patients with 
SLE. The microtitre plates were coated with RNS-DNA (2.5 l^g/ml). 
Cuirves (-•-), (-•-), (-A-), (-T-) represent sera from different SLE 
patients. 
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TABLE 9 
Inhibition of Anti-DNA Autoantibody Binding to Native DNA 
S.No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
MAXIMUM PERCENT 
INHIBITION AT 20 jig/tnl 
30 
28 
5 
20 
39 
16 
22 
50 
20 
30 
49 
39 
INHIBITOR CONCENTRATION 
REQUIRED FOR 50% INHIBITION 
(Hg/ml) 
-
-
-
-
-
-
-
20 
-
-
19.7 
82 
TABLE 10 
Inhibition of Anti-DNA Autoantibody Binding to RNS Human DNA 
S.No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
MAXIMUM PERCENT 
INHIBITION AT 20 ^g/ml 
52 
71 
69 
70 
52 
60 
62 
46 
37 
66 
60 
66 
INHIBITOR CONCENTRATION 
REQUIRED FOR 50% E^^iIBITION 
(Hg/ml) 
19 
1.0 
10 
9.0 
19 
13 
10 
-
-
4 
13 
11 
83 
was <0.05. At this defined degree of freedom the calculated t value is less at t 
distribution probability of 5.0%. Therefore, the data analyzed is significant. 
Purification of SLEIgG 
SLE IgG v^ 'as purified by affinity chromatography on Protein A-Sepharose CL-
4B column. The purified IgG eluted as a single peak (Fig. 30). Purity of IgG was 
checked by SDS-PAGE under non-reducing conditions. The purified IgG migrated as a 
single band. 
Band Shift Assay using SLE IgG 
Band shift assay was employed to visualize the interaction of native and RNS-
DNA with SLE IgG. A constant amount (l|ig) of antigen was incubated with varying 
amounts of SLE IgG (20 to 80 /ag) for 2 hr at 37°C and overnight at 4°C. The resulting 
immune complexes were then electrophoresed on 1% agarose for 90 min at 30 mA. An 
increase in the IgG concentration caused an increase in the immune complex formation 
which resulted in relative increase in molecular weight and consequently retarded 
mobility which was much pronounced in case of RNS-DNA due to increased recognifion 
of the modified polymer by SLE autoantibodies (Fig. 31). 
Antibodies against Native and RNS-DNA in Cancer Sera 
Sixty five serum samples were collected from patients suffering from cancer of 
different origin. Sera were collected from the indoor and outdoor patients, with well 
diagnosed malignancies, at the J.N. Medical College Hospital, A.M.U., AHgarh. Normal 
human sera (NHS) from healthy subjects served as negative control. 
The binding of circulating antibodies in cancer sera (at 1:100 dilution) with 
native and RNS-human DNA was assessed by direct binding ELISA. Out of 65 samples, 
all but two showed greater recognition for RNS-DNA than native human DNA (Fig. 32). 
The binding specificity of antibodies in cancer sera was analyzed by competitive 
binding assay (Table 11) Among the 64 serum samples tested, 40 sera showing greater 
recognition as indicated by direct binding ELISA were chosen and grouped accordingly. 
Out of these, six sera were from cancer of cervix and all of these sera were found to 
recognize RNS-human DNA to a greater extent than native human DNA (Fig. 33-34). 
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Fig. 30. Elution profile of SLE IgG on a Protein A-Sepharose CL-4B column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 31. Band shift assay of SLE IgG bincing to (a) native DNA and (b) RNS-
DNA. Native DNA and RNS-DNA (l|ag each) were incubated with IgG 
for 2 hr at 37°C and over night at ^°C. Electrophoresis was carried out on 
1% agarose gel for 2 hr at 33 mA. Lane 1 contain native or modified 
DNA while lanes 2, 3, 4 and 5 contain native or RNS-DNA with 10, 20, 
40, 80 fig of SLE IgG. 
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Fig. 32(a). Binding of various cancer sera to native (-•-) and modified DNA (-•-). 
The histogram show absorbance values for binding of NHS and sera from 
patients with different type of cancer. Microtitre plate was coated with 
RNS-DNA. (2.5 |Jg/ml). Serum no. 22 represents NHS which served as 
negative control. 
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Fig. 32(b). Binding of various cancer sera to native (-•-) and modified DNA (-Q-). 
The histogram show absorbance values for binding of NHS and sera from 
patients with different type of cancer. The microtitre plate was coated 
with RNS-DNA. (2.5 |ig/ml). Serum no. 43 represents NHS which served 
as negative control. 
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Fig. 32(c). Binding of various cancer sera to native (-•-) and modified DNA (-n-). 
The histogram show absorbance values for binding of NHS and sera from 
patients with different type of cancer. The microtitre plate was coated 
with RNS-DNA. (2.5 |Jg/ml). Serum no. 66 represents NHS which served 
as negative control. 
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TABLE 11a 
Inhibition in tlie Binding of Cancer Autoantibodies to RNS-DNA by Native 
and RNS-DNA. 
TYPE OF CANCER 
Cervix 
Head and neck 
Base of tongue 
Prostrate 
SERA TESTED 
(Number) 
6 
4 
5 
4 
MAXIMUM PERCENT INHIBITION 
AT 20 ng/ml 
NATIVE DNA 
21 
16 
20 
24 
22 
15 
27 
19 
10 
35 
18 
27 
19 
30 
23 
11 
38 
37 
36 
MODIFIED DNA 
28 
19 
41 
42 
38 
44 
56 
57 
27 
38 
40 
35 
39 
35 
35 
79 
60 
69 
69 
90 
TABLE l i b 
Inhibition in Tlie Binding of Antibodies in Cancer Sera to RNS-DNA by 
Native and RNS- DNA 
TYPE OF CANCER 
Lung 
Gall bladder 
Urinary bladder 
Breast 
SERA TESTED 
(Number) 
7 
4 
4 
10 
MAXIMUM PERCENT INHmiTION AT 
20 |ag/ml 
NATIVE DNA 
30 
36 
57 
48 
21 
23 
19 
20 
28 
34 
26 
17 
20 
18 
19 
21 
17 
23 
17 
25 
20 
19 
18 
20 
18 
MODIFIED DNA 
75 
73 
82 
19 
40 
51 
39 
33 
50 
47 
38 
25 
25 
26 
30 
20 
52 
53 
41 
45 
37 
16 
37 
34 
30 
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Fig. 33. Detection of antibodies against native DNA in the sera of patients with 
cancer of cervix . The microtitre plates were coated with RNS-DNA 
(2.5 ^g/ml). Curves (-•-), (-•-), (-A-), ( - • - ) , ( - • - ) , {-<-), 
represent sera from different patients with carcinoma cervix. 
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Fig. 34. Detection of antibodies against RNS-DNA in the sera of patients with 
cancer of cervix. The microtitre plates were coated with RNS-DNA (2.5 
^g/ml). Curves (-•-), (-•-), (-A-), (-T-), (-•-), ( - • - ) , represent 
sera from different patients with carcinoma cervix. 
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Maximum percent inhibition in antibody activity achieved by native human DNA was 
appreciably less (21%, 16%, 20%, 24%, 22%, and 14%) than that achieved by RNS-
human DNA (28%, 19%, 41%, 42%, 38% and 44%). The t value for n=6 was observed 
to be 6.60. Four sera were from patients of head and neck cancer and all of them had 
greater recognition for RNS human DNA (56%, 57%, 27% and 38%) as compared with 
native DNA, showing per cent inhibition of (27%, 19%, 4% and 35% ), respectively; t 
value for n = 4 was found to be 2.45 (Fig. 35-36). 
Five serum samples from patients with cancer of base of tongue showed higher 
recognition towards RNS human DNA in direct binding ELISA. The samples when 
subjected to inhibition studies caused an inhibition of (40%, 35%, 39%, 35% and 35% ) 
with RNS human DNA whereas, with native DNA the observed inhibition was ( 18%, 
27%, 19%, 30% and 22%) respectively; t value for n=5 was calculated to be 5.42 
(Fig. 37-38). 
Samples from patients with prostate cancer (4 in number) showed greater degree 
of inhibition in antibody activity when RNS-DNA was used as inhibitor ( 79%, 60%, 
69% and 69%) as compared to native DNA (11%, 38%, 37% and 36%) respectively 
(Fig. 39-40); t value for n - 4 was found to be 6.30. 
Among the samples analyzed, seven sera from patients with lung cancer were 
chosen for inhibition analysis and found to recognize RNS human DNA to a greater 
extent. Maximum percent inhibition obtained from these sera was (75%, 73%, 82%, 
0.0%, 40%, 51% and 59%) and (30%, 36%, 57%, 48%, 21%, 23%, 19%) with RNS 
human DNA and native human DNA respectively; t value for n = 7 was calculated to be 
2.32 (Fig. 41-42), (Table 12). 
Maximum percent inhibition of serum autoantibodies from patients of gall 
bladder malignancy achieved by RNS-human DNA was 33%, 50%, 47% and 48% (Fig. 
43-44). Native human DNA again caused appreciably less inhibition (20%, 26%, 34%, 
and 26%); t value for n = 4 was observed to be 3.00. 
Maximum percent inhibition of serum autoantibodies from patients with 
carcinoma urinary bladder achieved by RNS-human DNA was (25%, 25%, 26% and 
30%). Native human DNA was inhibitory to a lesser extent, showing maximum 
inhibition of (17%, 20%, 18% and 19% ) at an inhibitor concentration of 20 \ig/m\ 
(Fig.45-46); t value for n = 4 was found to be 5.50. 
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Fig. 35. Detection of antibodies against native DNA in the sera of patients with 
head and neck cancer. The microtitre plates were coated with RNS-DNA 
(2.5 |iig/m]). Curves (-•-), (-•-), (-A-), ( - • - ) represent sera from 
different patients with carcinoma head and neck. 
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Fig. 36. Detection of antibodies against RNS-DNA in the sera of patients with 
head and neck cancer. The microtitre plates were coated with RNS-DNA 
(2.5 Mg^ ml). Curves (-•-), (-•-), (-A-), ( - • - ) represent sera from 
different patients with carcinoma head and neck. 
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Fig. 37. Detection of antibodies against native DNA in the sera of patients with 
cancer of base of tongue. The microtitre plates were coated with RNS-
DNA (2.5 ug/ml). Curves (-•-), (-•-), (-A-), ( - • - ) , (-•-), represent 
sera from different patients with carcinoma base of tongue. 
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Fig. 38. Detection of antibodies against RNS-DNA in the sera of patients with cancer of 
base of tongue . The microtitre plates were coated with RNS-DNA (2.5 |ig/ml). 
Curves (-•-), (-•-), (-A-), ( - • - ) , (-•-), represent sera from different 
patients with carcinoma base of tongue. 
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Fig. 39. Detection of antibodies against native DNA in the sera of patients with 
prostrate cancer. The microtitre plates were coated with RNS-DNA 
(2.5 g/ml). Curves (-•-), (-•-), (-A-), ( - • - ) represent sera from 
different patients with carcinoma prostrate. 
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Fig. 40. Detection of antibodies against RNS - DNA in the sera of patients with 
cancer of prostrate. The microtitre plates were coated with RNS-DNA 
(2.5 Mg/rnl)- Curves (-•-), (-•-), (-A-), (-T-) represent sera from 
different patients with carcinoma prostrate. 
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Fig. 41. Detection of antibodies against native DNA in the sera of patients with 
lung cancer. The microtitre plates were coated with RNS-DNA (2.5 
ixg/ml). Curves (-•-) , (-•-) , (-A-), (-T-), (-•-), {-<-), ( - • - ) 
represent sera from different patients with carcinoma lung. 
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Fig. 42. Detection of antibodies against RNS - DNA in the sera of patients with 
lung cancer. The microtitre plates were coated with RNS-DNA 
(2.5 ^g/ml). Curves (-•-), (-•-), (-A-), (-T-), (-•-), ( -^-) , ( -^-) , 
represent sera from different patients with carcinoma lung. 
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TABLE 12 
Antibodies Against Native and RNS Modified Human DNA in Cancer Sera 
TYPE OF 
CANCER 
Cervix 
Head and neck 
Base of tongue 
Prostrate 
Lung 
Urinary bladder 
Breast 
NO. OF SERA 
TESTED 
6 
4 
5 
4 
7 
4 
10 
SERA 
POSITIVE FOR 
RNS -DNA 
5 
4 
5 
4 
6 
4 
8 
SERA 
POSITIVE FOR 
NATIVE -DNA 
-
2 
2 
3 
4 
-
1 
SERA 
POSITIVE FOR 
BOTH NATIVE 
AND RNS-
DNA 
-
2 
2 
3 
3 
-
1 
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Fig. 43. Detection of antibodies against native DNA in the sera of patients with 
gall bladder cancer. The microtitre plates were coated with RNS-DNA 
(2.5 )ig/ml). Curves (-•-) , (-•-) , (-A-), ( - • - ) , represent sera from 
different patients with carcinoma gall bladder. 
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Fig. 44. Detection of antibodies against RNS-DNA in the sera of patients with gall 
bladder cancer. The microtitre plates were coated with RNS-DNA 
(2.5 ^g/ml). Curves (-•-), (-•-), {-^-\ (-•-)» represent sera from 
different patients with carcinoma gall bladder. 
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Fig. 45. Detection of antibodies against native DNA in the sera of patients with 
cancer of urinary bladder. The microtitre plates were coated with 
RNS-DNA (2.5ng/ml). Curves (-•-), (-•-) , (-A-), (-T-) represent 
sera from different patients with carcinoma urinary bladder. 
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Fig. 46. Detection of antibodies against RNS-DNA in the sera of patients with 
cancer of urinary bladder. The microtitre plates were coated with 
RNS-DNA (2.5ng/ml). Curves (-•-), (-•-) , (-A-), (-T-) represent 
sera from different patients with carcinoma urinary bladder. 
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Among the ten sera collected from patients with carcinoma of breast all but two 
were found to be more reactive towards RNS human DNA (20%, 52%, 53%, 41%, 45%, 
37%, 16%, 37%, 34% and 30%) than the native analog (21%, 17%,23%, 17%, 25%, 
20%, 19%, 18%, 20% and 18% ) respectively (Fig. 47-50); t value for n=10 was 
calculated to be 4.70 (Table 13). 
Therefore, statistically it can be concluded that for all the different groups and 
types of sera tested the calculated t value is greater at t distribution probability p<0.5. 
The results are therefore significant and since r<l it can be inferred that the two 
variances i.e. modified and unmodified DNA serving as inhibitor do not have identical 
score, a common score ( which might be the phosphate back bone structure) only partly 
accounts for them and also for there covariance, that is why the obtained covariance and 
the product of separate variances are not equal, and native form of DNA show only some 
degree of cross reactivity with the induced antibodies ( Table 14). 
Purification of Cancer IgG 
Cancer IgG was purified by affinity chromatography on a Protein A Sepharose 
CL-4B column. The purified IgG eluted as a single peak (Fig. 51). Purity of IgG was 
checked by SDS-PAGE under non-reducing conditions. The purified IgG migrated as a 
single band. 
Band Shift Assay using Cancer IgG 
Since maximum inhibition with RNS-DNA was observed with the serum 
anfibodies from lung cancer pafients, band shift assay of nafive and RNS modified DNA 
was performed using IgG of lung cancer patient (Fig. 52). Constant amount of antigen 
(l)ag) was incubated with increasing concentration of cancer IgG (0-80 j^g). The immune 
complexes were incubated at 37°C for 2 hr and overnight at 4°C. The samples were 
electrophoresed on \% agarose at 30 mA. With increasing IgG concentrations there is a 
reduction in the mobility of unbound antigen. In case of RNS-DNA, the retardation was 
much more as compared to the native form of DNA. 
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Fig. 47. Detection of antibodies against native DNA in the sera of patients with 
breast cancer. The microtitre plates were coated with RNS-DNA 
(2.5 [ig/ml). Curves (-•-), (-•-) , (-A-), (-T-), (-•-), represent sera 
from different patients with carcinoma breast. 
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Fig. 48. Detection of antibodies against native DNA in the sera of patients with 
breast cancer . The microtitre plates were coated with RNS-DNA 
(2.5 |ig/ml). Curves (-•-), (-•-) , (-A-), ( - • - ) , (-•-), represent sera 
from different patients with carcinoma breast. 
110 
o 
EH 
I—I 
m 
t—I 
w 
I—I 
EH 
"A 
O 
p:5 
0 
20-
40-
60-
80-
100 ~ i — I — 1 1 1 1 1 1 T 1 I I I I I I T 1—I—r 
0.01 0.1 1 10 100 
INHIBITOR CONCENTRATION Cug/ml) 
Fig. 49. Detection of antibodies against RNS-DNA in the sera of patients with 
breast cancer. The microtitre plates were coated with RNS-DNA 
(2.5 ^g/ml). Curves (-•-), (-•-) , (-A-), ( - • - ) , (-•-), represent sera 
from different patients with carcinoma breast. 
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Fig. 50. Detection of antibodies against RNS-DNA in the sera of patients with 
breast cancer. The microtitre plates were coated with RNS-DNA 
(2.5 |ig/ml). Curves (-•-), (-•-), (-A-), (-T-), (-•-), represent sera 
from different patients with carcinoma breast. 
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FRACTION NUMBER 
Fig. 51. Elution profile of cancer sera IgG on a Protein-A-Sepharose CL-4B 
column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 52. Band shift assay of lung cancer IgG binding to (a) native DNA and (b) 
RNS-DNA. Native DNA and RNS-DNA (l^g each) were incubated with 
IgG for 2 hr at 37°C and over nignt at 4°C. Electrophoresis was carried 
out on 1% agarose gel for 2 hr at 30 mA. Lane 1 contain native or 
modified DNA while lanes 2, 3, 4 and 5 contain native or RNS-DNA with 
10,20,40,80 lag of cancer IgG. 
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TABLE 13 
Percent Inhibition Obtained Against ModiHed and Native Human 
DNA With Antibodies in Cancer Sera 
TYPE OF 
CANCER 
Cervix 
Head and neck 
Base of tongue 
Prostrate 
Lung 
Gall bladder 
Urinary bladder 
Breast 
NO. OF 
CASES 
6 
4 
5 
4 
7 
4 
4 
10 
INHIBITION AT 20 i^g/ml 
MINIMUM PERCENT 
INHIBITION 
ACHIEVED 
NATIVE 
DNA 
15 
10 
18 
11 
19 
20 
17 
17 
MODIFIED 
DNA 
19 
27 
35 
60 
19 
33 
25 
16 
MAXIMl 
INH 
AC] 
NATIVE 
DNA 
24 
35 
30 
38 
57 
34 
20 
25 
JM PERCENT 
IBITION 
SIEVED 
MODIFIED 
DNA 
44 
56 
40 
79 
82 
50 
30 
53 
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TABLE 14 
Statistical Analysis of Inhibition ELISA Results 
o >-
a> W o 
Cervical 
Head & 
neck 
Base of 
tongue 
Prostrate 
Lung 
Gall 
bladder 
Urinary 
bladder 
Breast 
SLE 
w 
o 
d 
6 
4 
5 
4 
7 
4 
4 
10 
12 
3 
10 
6 
8 
6 
12 
6 
6 
18 
22 
SD 
> 
< Z 
19.5±3.47 
21.25±11.40 
23.2±4.61 
30.5±11.2^ 
33.4±13.3 
26.0±5.0 
18.5±1.10 
19.8±2.47 
26.0±15.0 
< 
1 
C/5 
35.3±8.90 
44.75±12.26 
36.8±2.20 
69.2±6.70 
54.2±16.0 
42.0±6.80 
26.5±2.0 
35.5±11.60 
55.0±14.10 
"V-
0.2 
0.7 
0.83 
0.6 
0.28 
0.67 
0.22 
0.31 
0.20 
6.60 
2.45 
5.42 
6.3 
2.32 
3.0 
5.5 
4.7 
4.5 
e. a, 
<5% 
<5% 
< 5 % 
< 5 % 
<5% 
< 5 % 
<5% 
<5% 
<5% 
>5% 
>5% 
>5% 
>5% 
>5% 
>5% 
>5% 
>5% 
>5% 
# df — Degree of freedom. 
# SD — Standard deviation. 
#t - Student t test. 
#p — distribution probability. 
#r — Coefficient of correlation. 
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Fig. 53. Inhibition of binding of anti-RNS-DNA IgG by genomic DNA isolated 
from blood of normal subjects .The microtitre plates were coated with 
RNS-DNA (2.5ng/ml). The curves (-•-), (-•-) represent DNA isolated 
from normal individuals. 
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Fig. 54. Inhibition of binding of anti-RNS-DNA IgG by genomic DNA islolated 
from blood of cancer patients. The microtitre plates were coated with 
RNS-DNA (2.5 ng/ml). The curves (-•-) , (-•-) , represent DNA isolated 
from different individuals with lung cancer, (-A-), (-T-) breast cancer 
and (- • - ) , (-^4-) head and neck cancer. 
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Detection of Oxidative Lesions in DNA 
DNA was isolated from the blood of various cancer patients. Purity and 
concentrations of the DNA preparations were ascertained by A260 and A280 
measurements. DNA isolated from blood of normal healthy individuals served as control. 
Anti-RNS-DNA IgG was used as probe to detect the oxidative lesions in the 
DNA from cancer patients. Immune complexes, formed by incubating a fixed amount 
(30 \ig) of anti-RNS-DNA IgG with increasing concentrations (0 to 20 ^g /ml) of DNA. 
The immune complexes thus formed were applied on RNS-DNA (2.5 i^ g /ml) coated 
microtitre plates. Samples of DNA isolated from patients with lung cancer caused an 
inhibition of 63.1±6.8% for immune IgG binding to the immunogen. Samples of DNA 
were also isolated from patients of breast cancer and cancer of head and neck. An 
inhibition of 56±2.0% and 54.7±0.94% was observed in the binding of immune IgG to 
the immunogen. On the contrary, DNA isolated from normal healthy individuals showed 
negligible inhibition of 18.5±7.4% with anti-RNS-DNA IgG binding to the immunogen 
(Fig. 53-54). 
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Reactive oxygen and nitrogen species are generated both through chemical 
reactions in the environment. The most significant being the reactive species derived 
from metaboUsm of oxygen and nitrogen inside the cell. These species are capable of 
causing many kinds of cellular damage including DNA damage (Ames et al., 1993; 
Allies., 1989; Cerutti et al., 1994). Since DNA plays a central role in information 
transfer, the ROS or RNS which escapes cellular defence causes permanent or transient 
damage to DNA alongwith proteins and lipids leading to cancer and other human 
pathologies (Wei et al., 1997). 
Nitric oxide, a paramagnetic diatomic uncharged molecule with an unpaired 
electron and a half life of 2 to 30 seconds is a highly reactive specie and its production is 
linlced to endogenous human carcinogenesis, hiduction of apoptosis by NO has also been 
observed in cultures of macrophages and pancreatic p-cells. Macrophages exposed to 
nitric oxide exhibited typical morphology and showed DNA fragmentation indicating 
apoptotic cell death (Nicotera et al., 1995; Cerutti, 1994). 
Nitric oxide is also known to show genotoxic effects by abolishing cell growth 
which is a valuable parameter sensitive to different kinds of damage- membrane damage, 
energy depletion, organelle damage and enzyme release etc. (Stopper et al., 1999). 
Systems where O2'" (superoxide anion) and NO (nitric oxide) are produced 
simultaneously lead to the production of ONOO" (peroxynitrite radical) which is far 
more reactive and damaging than its precursors. ONOO" has a half life (ti/2) of <1 sec. 
and is capable of oxidative damage to a wide range of biological molecules e.g. nucleic 
acids, lipids, thiols etc. (Beckman et al., 1996; Maria et al., 1997). 
Like NO, the diatomic molecule, O2 is a free radical (Halliwell and Gutteridge, 
1999) sufficiently reactive to oxidize DNA directly at a measurable rate at body 
temperature, in part because its two unpaired electrons have parallel spin and this spin 
restriction precludes direct acceptance of two electrons by O2 (Halliwell and Gutteridge, 
1999). Some products of oxygen reduction such as superoxide (O2"" ) and hydrogen 
peroxide (H2O2) are capable of reacting with DNA directly except perhaps at levels 
above their physiological range (Halliwell and Aruoma, 1991). Singlet states of oxygen 
readily oxidize guanine, the most oxidizable base in DNA (Ravanat and Cadet, 1995; 
Epe, 1992) Hydroxy radical, OH, generates a multiplicity of products from all four 
bases e.g. OH can attack guanine at position 8, generating 8-hydroxyguanine radical that 
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can have various fates depending on the redox state of the environment e.g. the amount 
of 8-hydroxyguanine produced by a given amount of free radical attack on guanine in 
DNA rises as O2 concentration increases (Fuciarelh et al., 1990). Reactive species of 
nitrogen e.g. N2O3, HNO2 and ONOO" causes G-T transversions whereas deamination of 
adenine to hypoxanthine can result in transitions (AT^'GC). Nitration of guanine via 
RNS leads to the production of 8-nitroguanine (Halliwell, 1999). Spontaneous 
deamination reactions also occur in DNA over the long human life span (Lindahl, 1993). 
Role of nitrosative stress to DNA is also related to malignant transformations and 
to the etiology of autoimmune diseases like systemic lupus erythematosus (SLE) which 
is a multisystem autoimmune disease of unknown etiology. Over production of nitric 
oxide (NO) has been implicated in its pathogenesis (Oates et al., 1997). Several studies 
have indicated a correlation between serum nitrates/nitrites (NOx) and disease activity. 
Peroxynitrite (ONOO"), a product of NO and superoxide, nitrates tyrosine moieties. The 
resulting 3-nitrotyrosine (3NT) serves as a long-term indicator of NO-mediated protein 
modifications. (Wanchu et al., 1998). It has been studied and inferred that the serum 3NT 
is elevated among patients with disease activity. Correlation of 3NT with disease activity 
is significant among African-American lupus subjects and those with renal disease 
(Oates et al,, 1999). Besides modification of proteins, byproducts of NO are also capable 
of DNA modifications which leads to the generation of anti-DNA autoantibodies in the 
sera of SLE patients considered as a marker of the disease as well as pathogenic factor 
for its renal involvement (Koffler, 1974). 
In the present study peroxynitrite generated by synergistic action of a nitric oxide 
donor and pyrogallol caused extensive damage to the structure of DNA leading to single 
strand breaks. The damage to nitrogenous bases resulted in destruction of chromophoric 
groups as revealed by ultraviolet light absorption spectra of RNS-human DNA which 
exhibited hyperchromicity at 260 nm with reference to native human DNA. In presence 
of excessive nitric oxide or superoxide, peroxynitrite gets converted to nitrogen dioxide 
which is not damaging towards DNA. This argument is in full conformity with our 
results wherein it has been observed that the damaging action of SNP and pyrogallol is 
directly related to their concentration ratios. The DNA damage occurs only when SNP 
and pyrogallol are in 1:1 ratio. 
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Native structure of DNA is a flexible make up of ordinary molecules which are 
not packed with any quantum mechanical stability rather the structure is held by base 
stacking and hydrogen bonds thus high temperature disrupts these interactions and 
favours denaturation of DNA. The decrease in melting temperature and early onset of 
duplex melting as compared to the native DNA suggests reduced base stacking, presence 
of single strand breaks, and disruption of hydrogen bond as a consequence of RNS 
attack. 
Fluorescence is an emission phenomenon which measures energy transition from 
higher to lower state within the molecule, upon modification of human DNA by RNS the 
fluorescent properties of DNA gets altered such that the decrease in fluorescence spectra 
of RNS human DNA explains that the extrinsic fluor, ethidium bromide, which is a 
cyclic planar molecule can no more bind between the stacked base pair to the same 
extent as with native DNA where ethidium bromide concentration builds up at the 
ordered stacked helical structure. Therefore a decrease in quantum efficiency, fluorescent 
intensity and a stokes shift of 5 nm explains altered base stacking and disruption of 
hydrogen bonds. 
The structural alterations upon modification of human DNA with RNS when 
observed by 1% agarose gel electrophoresis renders it susceptible to single strand 
specific SI nuclease (Waris, 1999; Abdi, 1999). In view of this, native and RNS-human 
DNA were subjected to nuclease SI digestion and analyzed by electrophoresis on 1% 
agarose gels. The results showed substantial digestion in the case of RNS-DNA while the 
degree of digestion was quite reduced in the case of pyrogallol-DNA. Native human 
DNA and SNP-DNA remained undigested. This observation clearly demonstrates that 
sufficient single strand breaks are generated when native human DNA is subjected to 
modifications by RNS. The results of alkaline agarose gel electrophoresis reiterate the 
earlier observation that as a result of modification the DNA helix looses some of its 
stability due to generation of single strand breaks. Near vanishing of DNA band under 
alkaline electrophoresis clearly shows its susceptibility to alkaline digestion as against 
the native control which was only partially digested. 
Modification of human DNA in presence of different quenchers, specific towards 
a single radical, lead to the conclusion that maximum damage is caused when both NO 
and 0 2 " are generated, since PTIO (a known quencher of peroxynitrite radical) was able 
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to quench the reaction almost completely whereas the modification was prevented to 
some extent by ascorbic acid, uric acid and superoxide dismutase. It can also be said that 
there was no role of OH radical in the reaction since marmitol could not stop the 
modification of human placental DNA. The results lead to the conclusion that maximum 
damage results by the combined action of NO and 0 2 " radicals leading to the formation 
of peroxynitrite radical. Immunogenicity of RNS modified human DNA was evaluated 
by immunizing in rabbits. Immunological data suggests RNS human DNA to be a potent 
immunizing stimulus inducing high titre antibodies where as native human DNA and 
human DNA treated with SNP or pyrogallol were found to be weak immunogens. The 
results reiterate earlier studies which show that although native DNA per se is a poor 
immunogen, its oxidatively damaged analogs with altered bases and conformational 
variance from the standard B-form can trigger immune response. Double stranded RNA, 
RNA-DNA hybrids, double helical polydeoxyribonucleotides, DNA modified with drugs 
and hormones too have been found to induce antibodies. (Abdi, 1999; Moinuddin and 
AU 1994). 
The antigenic specificity of anti-RNS-human DNA IgG was ascertained by 
competitive binding assay. The IgG was found to have high affinity for the immunogen 
as only 10 ^g/ml of immunogen was required to inhibit 50% antibody activity. Besides, 
the immune IgG also showed some amount of cross reactivity towards native human 
DNA. This may be possible because of similarity in the sugar phosphate backbone or 
common antigenic determinants of native and modified DNA (Lafer et al., 1981; Rauch 
etal , 1985) 
In order to further confirm that the induced anti-RNS-DNA IgG has binding 
affinity towards antigenic determinants common to both native and RNS-DNA, band 
shift assay was performed which lead to the visual detection of interaction between 
immune IgG and the immunogen. The results revealed high affinity of anti-RNS-DNA 
IgG for the immunogen. Besides, lesser degree of binding was also observed with the 
native analog. 
Since the polyspecific binding nature was observed in the induced antibodies, 
they were allowed to cross react with different antigens with similar origin but of diverse 
nature. Native calf thymus, 400 bp calf thymus DNA and chromatin showed moderate 
reactivity with immune IgG which may be due to their common mammalian origin, 
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whereas their modified analogs, RNS-calf thymus DNA, O2'" 400 bp calf thymus DNA, 
ROS-chromatin exhibited higher recognition of anti-RNS-human-DNA IgG. Among 
these antigens RNS-calf thymus DNA showed maximum binding with the induced 
antibody indicating the preferential recognition of RNS-modified epitopes by immune 
IgG. DNA modified by superoxide radical (02'~) however, inhibited antibody activity 
to a lesser extent possibly because damage inflicted on DNA by 0 2 " produce epitopes 
not appreciably recognised by the antibodies (Abdi et al., 1999) 
Besides binding to various existing and modified forms of nucleic acids, anti-
RNS-human-DNA IgG also showed some degree of cross reactivity towards synthetic 
polynucleotides, cardiolipin and chondroitin sulphate. The results suggest that the cross 
reactivity might be due to mimicking of sugar phosphate moiety of cardiolipin with 
DNA. Therefore, it can be inferred that anti-RNS-human-DNA IgG appears to be 
polyspecific and the various cross reacting antigens with which it reacts share a common 
antigenic determinant. 
Anti-nuclear antibodies are best screening test if the test substrate contains human 
nuclei, more than 95% of lupus patients will be positive. Therefore a positive ANA is not 
specific for SLE rather it supports the diagnosis of SLE. Antibodies to double stranded 
DNA (dsDNA) and to Sm are relatively specific for SLE. Since the anti-dsDNA 
antibodies are polyspecific, it is suggestible that the pathogenic mechanism, in vivo, is 
probably through reactivity with molecules other than DNA which may lead to many 
clinical disorders. Since at onset, SLE may involve only one organ system but as the 
sjmdrome progresses it becomes multisystemic, due to additional manifestation of 
musculo-skeletal system, nervous system, cardiopulmonary system, renal lesions leading 
to glomerulonephritis caused by the deposition of circulating immune complexes or 
insitu complex formation in mesangium and glomerular basement membrane (Austin 
and Balow, 1999; Boumpas et al., 1995; Hohn, 1998) 
Therefore, it can be said that the SLE anti-DNA antibodies are polyspecific and 
suggests that the native DNA may not be the immunogen rather a non specific cross 
reactive event may lead to generation of such auto antibodies (Zack et al., 1995). It can 
be said that the polyspecific behaviour of anti-ROS-human DNA IgG in a way resembles 
the binding characteristics of SLE anti-DNA autoantibodies thus suggesting a somewhat 
common origin. 
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The antigenicity of RNS-human-DNA was investigated by characterizing SLE-
autoantibodies for their comparative binding towards native and modified DNA, and as 
expected the binding was more pronounced with the modified form of DNA. The 
binding specificities of SLE anti-DNA autoantibodies were further investigated through 
competition ELISA, and it was found that a maximum of 70% inhibition was achieved 
when RNS-human-DNA was used as an inhibitor, whereas native DNA could achieve a 
maximum inhibition of 50%. Also the calculated t value at df= 22 is significant at a level 
less than 0.05. The resuhs suggest significant stronger reactivity of RNS modified DNA 
towards SLE autoantibodies. 
RNS-DNA was further assessed to be one of the candidates for the origin of anti-
DNA autoantibodies in SLE through the binding of SLE IgG to native and RNS-human 
DNA in band shift assay. It was found that visible immune complexes showing increased 
intensity (thus amount) were formed in the case of RNS-DNA which were retained in the 
well and retarding DNA mobility as compared with controls. 
It has been reported that NO production is increased in patients with SLE; 
elevations of serum nitrate correlated with indices of disease activity (SLEDAI) and with 
serum titrates of dsDNA antibodies are indications of SLE. Our results also support the 
role of nitric oxide and its byproducts in SLE etiopathogenesis (Gilkeson et al., 1996). 
During the immune activated state characterized active SLE, iNOS is induced in a wide 
array of tissues in response to excessive cytokine production but was found to be a 
nonspecific event occurring in a wide variety of cell types and under different conditions 
e.g. ulcerative colitis, psoriasis, arthritis etc. Therefore the finding of increased NO 
production is non specific for SLE, rather a reflection of immune-activated state in 
which inflammatory cytokines and other mediators have upregulated iNOS in diverse 
tissues (Fang, 1997; Middleton et al. 1993; Kolb Bachofen et al, 1994; Parkinson et al., 
1997). 
It was also proposed that in chronic inflammatory diseases such as SLE, the 
phagocytic cells release reactive oxygen species which penetrate cellular membranes and 
react with nuclear DNA. Subsequent release of this altered DNA during apoptosis may 
enable it to act as an antigen inducing antibodies cross reacting with native DNA 
(Herrmann et al., 1996; Casciola-Rosen and Rosen, 1997). It has been reported that there 
is an increase in cancer incidence in most of the chronic inflammatory diseases such as 
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chronic hepatitis, systemic sclerosis and SLE (Boumpas et al., 1986; Petterson et al., 
1992; Lunec et al., 1994). Furthermore, many studies have reported elevated levels of 
antinuclear antibodies in sera of patients with malignancies (Chagnaud et al., 1992; 
Faiderbe et al., 1992; Becker, 1994; Ashok and Ali, 1998). 
It is well known that NO and its reactive derivatives e.g. 0N00~ are elevated in 
infection and inflammation and plays important role in carcinogenesis. (Oshima et al., 
1994; Wiseman et al., 1996). It has been found that carcinogenic effect of NO may be 
due to its cytotoxic potential which lead to reduced cell viability. 
In this part of study, decomplemented serum of cancer patients were tested for 
the presence of autoantibodies reactive towards native and RNS-human-DNA. In direct 
binding ELISA almost all cancer sera showed higher recognition of RNS-human-DNA 
by the circulating autoantibodies. The antigenic specificity of circulating antibodies was 
analyzed by competition binding assay. Increased levels of circulating antibodies and 
autoantibodies have been reported in sera of patients with malignancies (Anderson et al., 
1988b; Faiderbe et al., 1992; Becker et al., 1994). Elevated levels of antinuclear 
antibodies, upto 27%, in cancer have been reported (Zemonski et al., 1972). 
The data presented here, from various types of cancers like that of breast, head 
and neck, oral, gastric, colon, cervical, prostrate etc., clearly indicate the presence of 
circulating antibodies in cancer sera, highly reactive to RNS-DNA as compared to native 
human DNA. The findings indicate that RNS modification appears to enhance the 
antigenicity of human DNA and hence might be a contributory factor in the induction 
and elevated levels of the circulating antibodies, primarily against RNS-DNA, but cross 
reacting with native DNA. 
The incidence of head and neck cancers, comprising mainly of base of tongue, 
has been reported to be much higher in countries of eastern hemisphere than in the west. 
In India head and neck comprises about 29% of all the cancers and the incidence has 
increased to 1,37,000 cases annually . It is more prevalent in males (WHO, 1997).Oral 
cancer constitutes 1/3'^ '' of all cancers and in USA, cancer of this region constitutes about 
4.25% of all cancers (ICMR bulletin, 1995). 
The present studies, therefore, suggest a role of RNS damaged DNA in the 
production of autoantibodies in cancer patients. 
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The recognition of native and RNS-DNA by cancer antibodies was visually 
detected in gel retardation assay. DNA was isolated from blood of patients suffering 
from carcinoma of lung, breast, head and neck. DNA isolated from normal subjects 
served as control. DNA from patients with breast cancer recognized anti-RNS-DNA IgG 
appreciably and inhibited its activity by 56 ± 2 percent. Similar was the case with lung, 
head and neck cancer where the observed inhibition was 63.1 ± 6.8% and 54.7 ± 0.94% 
respectively at inhibitor concentration of 20 |j,g/ml. 
All these results indicate effective binding of anti-RNS-human DNA IgG to DNA 
isolated from cancer patients and reiterate RNS-induced oxidative/ nifrosative DNA 
lesions in cancer patients. 
Based on this study the following conclusions can be drawn. 
1. Modification of DNA was done through simultaneous production of superoxide 
and nitric oxide radical which lead to the generation of peroxynitrite. 
2. Reactive nitrogen species, peroxynitrite in particular, are quite damaging towards 
DNA. 
3. Reactive nitrogen species modified DNA resulted in the formation of strand 
breaks, disruption of hydrogen bonds and a consequent helix destabilization. 
4. Thermal transitions showed that the modified conformers are less stable as 
compared to native form. 
5. A decrease in fluorescence intensity along with quantum efficiency explains 
altered base stacking and disruption of hydrogen bonds. 
6. RNS modified human DNA was found to be highly immunogenic in 
experimental animals. 
7. Competitive inhibition data shows that induced antibodies were specific towards 
the immunogen. 
8. The induced antibodies were found to be polyspecific exhibiting binding with 
native DNA, synthetic nucleic acid polymers and other cell macromolecules. 
9. Anti-RNS-DNA recognizes RNS-modified conformers better than their native 
analogs. 
10. Circulating SLE anti-DNA antibodies were found to be more reactive towards 
RNS-DNA than native DNA. 
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11. Antibodies in sera of various cancer patients were found to be more specific for 
RNS-DNA than for its native analog. 
12. Oxidative or nitrosative lesions were found in DNA isolated from blood of cancer 
patients. 
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